Colorectal & GI Cancer — 200 Frequently Asked Questions

Colorectal cancer (CRC) arises in the colon (large intestine) or rectum and is one of the three most common cancers in both men and women worldwide. In India, CRC incidence is rising steadily — particularly in urban populations — linked to changing diet, sedentary lifestyle, and obesity. When detected at Stage I, CRC is curable in over 90% of cases. Colonoscopy screening from age 45 prevents most colorectal cancers by identifying and removing pre-cancerous polyps before they become invasive. Any persistent change in bowel habit, rectal bleeding, or unexplained anaemia must be investigated promptly — early detection transforms outcomes dramatically.

Colorectal cancer arises from complex interactions between genetic predisposition, diet, lifestyle, and environmental factors. Established risk factors: age above 50 (85% of cases); personal or family history of CRC or adenomatous polyps; inflammatory bowel disease (ulcerative colitis, Crohn's disease); hereditary syndromes — Lynch syndrome (MLH1, MSH2, MSH6, PMS2 mutations) and Familial Adenomatous Polyposis (APC mutation); diet high in red and processed meat; low dietary fibre; physical inactivity; obesity; smoking; and alcohol consumption. Protective factors include: high-fibre diet, regular exercise, aspirin in high-risk individuals, and colonoscopic polypectomy. 75% of cases arise in individuals with no family history — reinforcing the importance of population-level screening.

Warning signs requiring prompt investigation: rectal bleeding — blood in stool or on toilet paper; any rectal bleeding in an adult must be evaluated, never assumed to be haemorrhoids without colonoscopic confirmation. Change in bowel habit lasting more than 3 weeks — increased frequency, looser stools, constipation, or alternating pattern. Passage of mucus per rectum. Sensation of incomplete evacuation — tenesmus. Unexplained iron deficiency anaemia — right-sided colon cancer bleeds slowly causing anaemia without visible blood in stool. Significant unexplained weight loss. Lower abdominal cramps or pain. Palpable abdominal or rectal mass. Early colorectal cancer is frequently completely asymptomatic — detectable only by colonoscopic screening. Any persistent symptom beyond 4 weeks warrants urgent colonoscopy.

Lynch syndrome — caused by germline mutations in mismatch repair (MMR) genes MLH1, MSH2, MSH6, or PMS2 — is the most common hereditary colorectal cancer syndrome, accounting for approximately 3% of all cases. Lifetime colorectal cancer risk is 50–80%; endometrial cancer risk 30–60%; ovarian, gastric, urological, and biliary cancers also elevated. All colorectal cancers should be tested for MMR deficiency by IHC staining — dMMR or MSI-high tumours are candidates for immunotherapy with pembrolizumab and respond dramatically better than MMR-proficient tumours. Lynch syndrome patients are recommended extended colectomy (subtotal or total) to reduce metachronous cancer risk. First-degree relatives carry a 50% mutation risk — genetic counselling and testing are essential.

FAP is caused by germline mutations in the APC gene — resulting in hundreds to thousands of colonic adenomatous polyps developing from adolescence, with near-100% lifetime risk of colorectal cancer if untreated. Diagnosis: flexible sigmoidoscopy from age 12–15 in known APC carriers; genetic testing for at-risk family members. Treatment: prophylactic total colectomy with ileorectal anastomosis or restorative proctocolectomy (pouch surgery) — typically performed in the late teens or early 20s before invasive cancer develops. FAP is also associated with upper GI polyps (duodenal and ampullary), desmoid tumours, and other extracolonic manifestations. Annual upper GI endoscopy is mandatory for FAP patients. Genetic testing of first-degree relatives is essential — children of a FAP carrier have a 50% risk.

Colorectal cancer screening detects cancer and pre-cancerous polyps before symptoms develop. Colonoscopy every 10 years from age 45 for average-risk individuals — colonoscopy is the gold standard as it both detects and removes polyps in the same procedure. Faecal Immunochemical Test (FIT) annually is an alternative for those unable to have colonoscopy — a positive FIT requires colonoscopy. CT colonoscopy (virtual colonoscopy) detects polyps above 6mm but cannot remove them. High-risk individuals — family history of CRC or polyps, Lynch syndrome, FAP, personal history of polyps or IBD — should begin colonoscopic surveillance from age 35–40 or 10 years before the youngest affected relative. Silver Leaf Clinic provides cancer risk assessment and screening recommendations. Call 88558 10010.

TNM staging classifies colorectal cancer by three dimensions. T (Tumour) describes depth of bowel wall invasion: T1 — into submucosa; T2 — into muscularis propria; T3 — through muscularis propria into pericolorectal tissue; T4a — penetrating visceral peritoneum; T4b — invading adjacent organs. N (Nodes) describes regional lymph node involvement: N0 — no nodes; N1 — 1–3 nodes; N2 — 4 or more nodes. M (Metastasis): M0 — no distant spread; M1a — single distant organ; M1b — multiple distant organs; M1c — peritoneal metastases. Stage I is T1-2 N0 M0; Stage II is T3-4 N0 M0; Stage III is any T N1-2 M0; Stage IV is any T any N M1. Stage directly determines surgical approach, adjuvant treatment, and prognosis.

Colorectal cancer survival is strongly stage-dependent, making early detection the most important factor. Stage I: 5-year survival 90–95% — excellent outcomes with surgery alone. Stage II: 75–85% — surgery with or without adjuvant chemotherapy depending on high-risk features. Stage III: 40–80% depending on nodal burden — surgery followed by 6 months FOLFOX or CAPOX chemotherapy reduces recurrence by 30%. Stage IV (metastatic): 5–15% overall, but surgical resection of limited metastases (liver or lung) achieves 30–50% five-year survival. Stage IV colorectal cancer spread to the peritoneum alone: CRS+HIPEC achieves 25–35% five-year survival. Early detection through screening colonoscopy is the most powerful strategy to shift patients from Stage III/IV at diagnosis to Stage I/II.

Mismatch repair (MMR) proteins — MLH1, MSH2, MSH6, PMS2 — detect and correct errors in DNA replication. When these proteins are deficient (dMMR) due to germline mutation (Lynch syndrome) or somatic epigenetic silencing (sporadic), tumours accumulate thousands of mutations producing a microsatellite instable (MSI-high) phenotype. dMMR/MSI-H colorectal cancer: accounts for approximately 15% of all CRC; has better prognosis at Stage II but does not benefit from 5-FU based adjuvant chemotherapy (no benefit, possibly harmful); and responds dramatically to immunotherapy — pembrolizumab as first-line treatment for metastatic dMMR CRC achieves response rates of 45% and durable remissions. All colorectal cancers should be tested for MMR status by IHC staining — this single test impacts both treatment choice and genetic counselling.

KRAS and NRAS (collectively RAS) mutations are present in approximately 55% of colorectal cancers. RAS mutations predict resistance to anti-EGFR targeted therapy — cetuximab (Erbitux) and panitumumab are only effective in RAS wild-type (mutation-free) tumours. RAS testing is mandatory before starting anti-EGFR therapy — treating RAS-mutant patients with anti-EGFR drugs offers no benefit and exposes patients to toxicity without efficacy. RAS wild-type left-sided metastatic CRC benefits most from cetuximab plus FOLFIRI or FOLFOX — achieving response rates and survival significantly better than chemotherapy alone. BRAF V600E mutation (10% of CRC) predicts poor prognosis and resistance to standard therapy — BRAF-mutant CRC is treated with encorafenib plus cetuximab (BEACON-CRC trial) after first-line failure.

Bowel preparation (bowel prep) clears stool from the colon before colonoscopy — essential for adequate visualisation of the mucosal surface. Standard prep: clear liquid diet the day before the procedure; polyethylene glycol (PEG) solution or sodium picosulphate-magnesium citrate taken in split doses — the evening before and 4–6 hours before the procedure (split-dose prep). The split-dose regimen improves cleansing quality and adenoma detection rate compared to single-dose prep. Common side effects: nausea, bloating, and cramping during prep. Low-volume prep options (sodium picosulphate, sodium phosphate) are available for patients who struggle with PEG volumes. Patients on anticoagulation or antiplatelet drugs need specific instructions regarding dose modification before colonoscopy. Adequate preparation is the most important factor in colonoscopy quality.

MDT — Multidisciplinary Team — review for colorectal cancer brings together the colorectal surgeon, medical oncologist, radiation oncologist, diagnostic radiologist (reviewing MRI and CT), histopathologist, and specialist nurse to reach a consensus treatment plan for every patient. For rectal cancer, MDT review determines: whether neoadjuvant chemoradiation is needed before surgery; the exact surgical approach (LAR versus APR); the quality of the MRI — whether the circumferential resection margin (CRM) is threatened; and whether Watch and Wait (organ preservation) is appropriate after complete response. No patient should proceed to colorectal cancer surgery without MDT review. At Sahyadri Manipal Hospital Pune, Dr. Gore presents every new colorectal cancer case at the weekly MDT before any treatment is planned.

MRI of the pelvis is the gold standard for local staging of rectal cancer — providing critical information that cannot be obtained from CT alone. MRI accurately assesses: tumour T-stage and depth of invasion; involvement of the circumferential resection margin (CRM) — the most important predictor of local recurrence; mesorectal fascia involvement; extramural vascular invasion (EMVI) — predicting systemic recurrence risk; and lymph node morphology. High-resolution MRI at a 3 Tesla magnet is preferred. MRI restaging after neoadjuvant chemoradiation (restaging MRI at 6–8 weeks after completing treatment) assesses response — guiding the decision between surgery, Watch and Wait, and the timing and extent of surgical resection. Every rectal cancer patient must have a high-quality pelvic MRI before treatment planning.

CT of the chest, abdomen, and pelvis (CT CAP) is the primary staging investigation for colorectal cancer — detecting liver metastases, lung metastases, peritoneal deposits, and involved lymph nodes. CT is less accurate than MRI for local rectal cancer staging (T-stage and CRM assessment) — MRI is always added for rectal cancer. CT colonography (virtual colonoscopy) is used when optical colonoscopy is incomplete (tortuous colon, obstructing tumour preventing passage of the scope) — detecting synchronous cancers or polyps in the unexamined colon proximal to the obstructing tumour. CT-guided biopsy is used for tissue confirmation of metastatic deposits in the liver or lung before systemic treatment. PET-CT is added for equivocal liver or lung lesions and for cases where HIPEC is being planned.

Colorectal cancer diagnosis requires tissue confirmation by biopsy — obtained during colonoscopy or flexible sigmoidoscopy. The endoscopist passes biopsy forceps through the scope and takes 4–6 tissue samples from the tumour. Biopsy samples are processed by histopathology and reported as: adenocarcinoma (the most common, 95%); mucinous adenocarcinoma (10–15%, associated with MSI-H); signet ring cell carcinoma (rare, poor prognosis); neuroendocrine carcinoma (rare); or squamous cell carcinoma (most common in the anal canal, not the rectum or colon). IHC staining for MMR proteins (MLH1, MSH2, MSH6, PMS2) is performed on every CRC biopsy — this single test identifies Lynch syndrome candidates and determines immunotherapy eligibility. RAS and BRAF mutation testing follows from the resected surgical specimen in most cases.

CEA (Carcinoembryonic Antigen) is a glycoprotein tumour marker elevated in 70–80% of colorectal cancers. Pre-operative CEA: elevated CEA (above 5 ng/mL) is an independent adverse prognostic factor in Stage II and III CRC; very high CEA (above 200 ng/mL) suggests liver metastases or peritoneal disease even if not yet visible on imaging. Post-operative CEA: should fall to normal (below 5 ng/mL) within 6 weeks of R0 resection — failure to normalise suggests residual disease. Surveillance CEA: measured every 3–6 months for 3 years after curative surgery — a rising CEA is often the first sign of recurrence, preceding CT findings by 3–6 months and enabling earlier intervention. CEA is not specific enough for primary diagnosis alone — it must always be interpreted with imaging and clinical assessment.

Colon cancer and rectal cancer share the same underlying biology (adenocarcinoma) but differ critically in treatment approach due to anatomical location. Colon cancer: treated primarily with surgery — laparoscopic or robotic colectomy — with adjuvant chemotherapy for Stage III disease. Neoadjuvant treatment is not routine for colon cancer. Rectal cancer: treatment is substantially more complex — most locally advanced rectal cancers (Stage II–III) receive neoadjuvant chemoradiation before surgery; robotic TME in the narrow pelvis is the gold standard surgical approach; sphincter preservation versus permanent stoma is a key decision; and post-operative bowel function (LARS) is an important quality-of-life consideration not relevant to colon cancer. The dividing point between colon and rectum is 15cm from the anal verge on rigid sigmoidoscopy.

Synchronous colorectal cancer is the presence of two or more primary colorectal cancers diagnosed simultaneously — occurring in 2–4% of colorectal cancer patients. The significance: all patients newly diagnosed with colorectal cancer must have complete colonoscopic evaluation of the entire colon to exclude synchronous tumours. When obstruction prevents complete colonoscopy pre-operatively, CT colonography is performed. Synchronous cancers may be managed by extended resection (removing more colon to include both tumours in one specimen) or staged operations. The presence of synchronous tumours in a young patient strongly suggests an underlying hereditary syndrome — Lynch syndrome or FAP — triggering genetic testing. Annual colonoscopy surveillance after resection is recommended for patients with synchronous cancer history.

Metachronous colorectal cancer is a second primary colorectal cancer developing after the original cancer has been treated — diagnosed more than 6 months after the initial resection. It is distinct from recurrence or metastasis — it represents a new primary tumour arising from previously normal mucosa. Risk: 1–3% lifetime risk of metachronous CRC after first colorectal cancer resection — significantly higher in Lynch syndrome patients (15–40%). Prevention: structured post-operative colonoscopy surveillance at 1 year, 3 years, and then every 5 years; more frequent surveillance for Lynch syndrome patients (every 1–2 years). Aspirin reduces metachronous adenoma and cancer risk in Lynch syndrome patients (CAPP2 trial). CEA monitoring detects recurrence but not new primary tumours — colonoscopy surveillance is essential.

Colorectal cancer recurrence after apparently curative surgery occurs in 30–40% of Stage III patients and 15–20% of Stage II patients within 3 years. Types: local recurrence — tumour returning at the anastomosis or in the pelvis; systemic recurrence — liver, lung, peritoneal metastases. Surveillance: CT chest/abdomen/pelvis every 6 months for 3 years, then annually for 5 years; CEA every 3 months for 3 years; colonoscopy at 1 year and every 3–5 years. Most recurrences occur within the first 3 years — the surveillance schedule is front-loaded accordingly. Isolated liver or lung recurrence is potentially curable with surgery — hepatectomy or pulmonary metastasectomy achieves 30–50% five-year survival in carefully selected patients. Early detection through structured surveillance is essential for curative salvage surgery.

Colectomy removes the cancer-bearing segment of colon with an adequate margin of normal bowel on either side, together with the supplying artery and its associated lymph nodes — the mesentery. The extent of resection is determined by tumour location: right hemicolectomy for caecum and ascending colon tumours; extended right hemicolectomy for hepatic flexure tumours; transverse colectomy for mid-transverse colon; left hemicolectomy for descending colon; and sigmoid colectomy for sigmoid tumours. After resection, the two bowel ends are joined (anastomosis) — restoring normal bowel continuity in most cases. A defunctioning stoma is rarely needed for elective colon cancer surgery in non-emergency settings. Laparoscopic or robotic colectomy is the standard approach at specialist centres.

Laparoscopic colectomy removes the cancer-bearing colon segment through 4–5 small port incisions (5–12mm) and a small extraction incision (4–6cm). Multiple large RCTs — COST trial (USA), CLASSIC trial (UK), COLOR trial (Europe) — confirm equivalent 5-year survival, local recurrence, and lymph node yield to open colectomy, with significantly better short-term outcomes: less blood loss, shorter hospital stay (3–5 vs 7–10 days), less post-operative pain, and faster return to work. Robotic colectomy extends these benefits with 3D magnification and wristed instruments enabling higher-quality Complete Mesocolic Excision (CME) and intracorporeal anastomosis. Laparoscopic colectomy is the standard of care for elective colon cancer surgery at specialist centres.

CME — Complete Mesocolic Excision — is the oncological gold standard for colon cancer surgery, analogous to TME for rectal cancer. It involves sharp dissection along the embryological mesocolic-to-parietal fascial plane — keeping the colonic mesentery completely intact and unbroken — combined with high ligation of the feeding artery at its origin at the superior or inferior mesenteric artery. CME maximises lymph node yield (achieving higher node counts) and ensures complete removal of the lymphovascular drainage territory of the tumour. Studies from Germany (Hohenberger group) and Japan demonstrate CME achieves 15–20% higher five-year survival in Stage III colon cancer compared to conventional colectomy. Robotic surgery facilitates high-quality CME with superior visualisation of the mesocolic planes.

Right hemicolectomy removes the caecum, ascending colon, hepatic flexure, and proximal transverse colon — for cancers of the caecum, ascending colon, and hepatic flexure. The ileocolic artery is ligated at its origin from the superior mesenteric artery (SMA) for CME. The terminal ileum is anastomosed to the transverse colon (ileocolic anastomosis) either intra-corporeally (robotic) or extra-corporeally through a small extraction incision. Lymph node yield should exceed 12 for adequate staging. Right-sided colon cancers present differently from left-sided — more often causing anaemia than obstruction; they have higher rates of MSI-high pathology and BRAF mutation; and they carry a different prognosis and chemotherapy sensitivity profile. Robotic right hemicolectomy with intracorporeal anastomosis is technically superior and increasingly standard.

Sigmoid colectomy removes the sigmoid colon for sigmoid cancer — including ligation of the inferior mesenteric artery (IMA) at its origin or just distal to the left colic artery branch, depending on the tumour's precise location and lymphovascular drainage pattern. The descending colon is anastomosed to the rectosigmoid junction or upper rectum. Hospital stay after laparoscopic or robotic sigmoid colectomy is 3–5 days. The sigmoid colon is the most common site of colorectal cancer (30–35% of all CRC). Diverticular disease frequently co-exists in the sigmoid — prior diverticulitis causing pericolic inflammation increases technical difficulty of laparoscopic or robotic resection. Hartmann's procedure — sigmoid resection with end colostomy without anastomosis — is reserved for emergency sigmoid resection with peritoneal contamination or perforation.

Risks of colectomy include: anastomotic leak — breakdown of the bowel join occurring in 3–5% of cases; the most serious complication requiring re-operation in severe cases. Wound infection — lower with laparoscopic approach. Ileus — temporary cessation of bowel activity, usually lasting 2–4 days; prolonged ileus requiring nasogastric tube in 5–10%. Bleeding — intraoperative or post-operative. Ureter injury — rare but serious with sigmoid resection. DVT and pulmonary embolism — prevented by early mobilisation, compression stockings, and low molecular weight heparin starting 12 hours after surgery. Long-term risks: incisional hernia (lower with laparoscopic approach); adhesional bowel obstruction (5–10% lifetime risk). All risks are discussed in detail at the pre-operative consultation. Operating at a specialist centre with high operative volume directly reduces complication rates.

Obstructing colon cancer (10–30% of presentations) requires emergency or urgent surgical management. Right-sided obstruction: right hemicolectomy with primary ileocolic anastomosis is usually safe even in emergency settings. Left-sided obstruction: three options. Hartmann's procedure — sigmoid resection with end colostomy, leaving the rectal stump closed; avoids anastomosis in an unprepared, contaminated colon; colostomy reversed as a second operation. Primary resection and anastomosis with on-table lavage — in selected fit patients. Self-expanding metal stent (SEMS) — placed endoscopically to relieve obstruction, converting an emergency operation to an elective planned resection 2–4 weeks later; enables laparoscopic surgery and avoids stoma in most cases. SEMS is increasingly preferred as a bridge to surgery for fit patients without perforation or peritonitis.

The technical challenges of right and left laparoscopic colectomy differ significantly. Right hemicolectomy requires dissection in the proximity of the superior mesenteric vessels — the ileocolic artery, right colic artery (when present), and the right branch of the middle colic artery. Intracorporeal anastomosis (bowel join performed inside the abdomen using staplers) produces superior results to extracorporeal anastomosis for right hemicolectomy — reducing incisional hernia and wound complications. Left and sigmoid colectomy require identification and preservation of the ureter (crossing the iliac vessels) and the hypogastric nerves (preserving bladder and sexual function) during mesenteric dissection. The robotic platform improves both right and left colectomy — particularly for CME dissection in the correct mesocolic fascial plane.

Adjuvant chemotherapy after curative colon cancer resection reduces recurrence risk by eliminating microscopic systemic disease that surgery cannot remove. Standard regimens: FOLFOX — 5-FU, leucovorin, oxaliplatin — 6 months; or CAPOX — capecitabine plus oxaliplatin — 3 months (IDEA trial demonstrated 3 months CAPOX is equivalent to 6 months for N1 disease). Recommended for: all Stage III (node-positive) colon cancer; selected high-risk Stage II colon cancer — T4 tumour, fewer than 12 lymph nodes retrieved, perineural or lymphovascular invasion, poorly differentiated histology, or clinical perforation/obstruction. Not recommended for Stage II dMMR/MSI-H tumours — these have good prognosis and may be harmed by 5-FU. Chemotherapy starts 4–6 weeks after surgery once wound healing is confirmed by clinical review.

FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) is the standard neoadjuvant chemotherapy regimen for resectable gastric and gastroesophageal junction cancer — not typically used for colon cancer. Colon cancer is generally treated with surgery first, followed by adjuvant FOLFOX or CAPOX for Stage III disease. However, neoadjuvant chemotherapy for colon cancer is being explored in specific situations: T4b locally advanced colon cancer invading adjacent organs — neoadjuvant FOLFOX aims to downstage before resection; synchronous resectable liver metastases — perioperative chemotherapy (FOLFOX before and after combined colon and liver resection) improves outcomes in selected patients. For metastatic colon cancer, FOLFOX, FOLFIRI, or FOLFOXIRI combinations — with or without bevacizumab, cetuximab, or panitumumab — are the backbone of systemic treatment.

Hartmann's procedure removes a segment of colon (most commonly sigmoid) and creates an end colostomy — without constructing an anastomosis. The distal colon or rectum is closed and left in the abdomen as a Hartmann's pouch. It is used in emergency settings: obstructing left-sided colon cancer; perforated diverticulitis; and pelvic trauma. Hartmann's reversal — restoring bowel continuity — is performed 3–6 months later as a planned elective second operation, reconnecting the colostomy to the Hartmann's pouch via laparoscopic or open approach. Reversal is technically demanding due to adhesions from prior emergency surgery. Unfortunately, reversal rates are lower than hoped — 40–60% in published series — because patient comorbidity, advanced cancer, or anastomotic risk preclude it. All options are discussed at consultation before emergency or elective Hartmann's procedure.

T4 colon cancer has grown through the bowel wall to involve adjacent structures: T4a — the tumour has penetrated the visceral peritoneum (creating a perforation or surface breach); T4b — the tumour has directly invaded adjacent organs including the small bowel, bladder, uterus, ovaries, ureter, or abdominal wall. T4b tumours require en bloc multivisceral resection — removing the colon together with all attached structures in one intact specimen without disrupting the plane between tumour and adjacent organ. Splitting the tumour from the adherent structure (separating them when adhesion may contain microscopic cancer) results in positive margins and dramatically increases local recurrence. R0 en bloc resection achieves 5-year survival of 45–55% for T4b N0 M0 colon cancer. Pre-operative MDT review is essential to plan adequate margins and reconstruct resected structures.

Transverse colectomy removes the mid-transverse colon for tumours at the hepatic or splenic flexure, or mid-transverse colon — requiring ligation of the middle colic artery at its origin from the SMA for adequate CME. The transverse colon is the most technically challenging segment for laparoscopic resection — requiring mobilisation of both flexures and wide mesenteric dissection. Extended right hemicolectomy (extending the right resection to include the hepatic flexure and mid-transverse colon) is more commonly performed than pure transverse colectomy. Extended left hemicolectomy includes the splenic flexure and part of the transverse colon. The anastomosis is typically ileocolic (extended right) or colocolic (extended left). Splenic flexure mobilisation is the most technically demanding step — requiring meticulous dissection to avoid splenic capsule injury.

Subtotal colectomy removes all of the colon from the caecum to the sigmoid — leaving the rectum intact — with ileostomy or ileorectal anastomosis. Indications: Lynch syndrome patients — reducing metachronous cancer risk by removing the entire at-risk colon; synchronous right and left colon cancers not amenable to standard segmental resection; obstructing left colon cancer with a grossly dilated right colon at risk of caecal perforation (right colon too compromised for primary anastomosis); and emergency presentation with pan-colonic involvement. After subtotal colectomy with ileorectal anastomosis, patients retain normal rectal function but may have 4–6 loose stools per day initially — improving over 3–6 months. Annual flexible sigmoidoscopy of the retained rectum is mandatory — the residual rectum remains at cancer risk in Lynch syndrome patients.

Colorectal cancer in pregnancy is rare but represents one of the most challenging oncological situations — requiring careful balancing of cancer treatment with fetal wellbeing. First trimester: surgical resection carries significant risk of miscarriage; chemotherapy is contraindicated. Second trimester: surgery is safest — performed laparoscopically where possible; chemotherapy can be given with relative safety from week 14 onwards. Third trimester: early delivery followed by cancer treatment is often the optimal strategy. MDT review involving the colorectal surgeon, medical oncologist, and obstetrician is mandatory for every case. The cancer must be treated with oncological adequacy — delaying definitive treatment risks disease progression. Each case requires highly individualised decision-making. Long-term cancer outcomes are equivalent to non-pregnant patients when treatment is not significantly delayed.

Splenic flexure mobilisation frees the colon at the point where it bends near the spleen — required for: left hemicolectomy and sigmoid resection (to achieve a tension-free anastomosis by lengthening the descending colon); anterior resection for rectal cancer (to bring the proximal colon into the pelvis without tension); and extended right hemicolectomy. The splenic flexure is held by the splenocolic ligament — careless division risks capsular tear and splenic bleeding requiring splenectomy. Medial-to-lateral and lateral-to-medial approaches are both used. Adequate mobilisation ensures a tension-free anastomosis — the most important factor in preventing anastomotic leak. Failure to adequately mobilise the splenic flexure is a common cause of anastomotic tension and subsequent leak in left-sided resections.

Intraoperative colonoscopy is performed during colon cancer surgery when pre-operative colonoscopy was incomplete — usually because the obstructing tumour prevented passage of the scope past the cancer. The surgeon passes the colonoscope through the ileostomy or via the anus after resection to examine the proximal colon for synchronous polyps or cancers. Any synchronous lesions found can be tattooed for subsequent colonoscopic surveillance, or managed by extended resection at the same operation if oncologically indicated. The yield of intraoperative colonoscopy finding significant synchronous lesions is approximately 5–10%. This step ensures no synchronous cancer is missed — which would be catastrophic if left in situ while the primary cancer is treated with adjuvant chemotherapy.

Anastomotic leak occurs when the surgical join between two bowel ends breaks down — allowing bowel contents to leak into the abdomen. It occurs in 3–5% of colonic anastomoses and 5–10% of low rectal anastomoses. Risk factors: male sex, obesity, smoking, diabetes, malnutrition, steroid use, radiation to the pelvis, and tension on the anastomosis. Signs: fever, rising CRP, deteriorating clinical condition on day 3–5 post-operatively; CT scan with oral or rectal contrast confirms the leak. Management: minor contained leak — nil by mouth, antibiotics, and radiological drainage; major leak with generalised peritonitis — emergency re-operation, washout, and stoma formation. ICG fluorescence used intraoperatively confirms adequate blood supply to the anastomosis before completion — dramatically reducing clinically significant leak rates.

Port-site metastasis — cancer cells implanting at the laparoscopic port sites — was a concern in the early days of laparoscopic colorectal surgery but has been proven to be no more common than wound recurrence after open surgery when correct oncological technique is used. Prevention: intact specimen retrieval using a wound protector (plastic sleeve) preventing direct tumour contact with the port site; avoiding tumour perforation during laparoscopic manipulation; and meticulous instrument handling. Port-site recurrence rates in modern laparoscopic colorectal cancer surgery are under 1% — equivalent to open surgery wound recurrence rates. Gallbladder cancer is a notable exception — laparoscopic cholecystectomy for unsuspected cancer carries a higher port-site metastasis risk, requiring specific management including port-site excision.

Recovery after laparoscopic colectomy follows ERAS (Enhanced Recovery After Surgery) principles. Day of surgery: IV drip stopped, drinking water within 4 hours; mobilisation sitting out of bed. Day 1: Walking in the ward; light diet — tea, biscuits; drain removed if output is clear and low. Day 2–3: Progressing to normal diet; physiotherapy for breathing exercises and mobilisation. Hospital discharge: day 3–5 in most cases. Home recovery: light activities from week 1; driving at 2–3 weeks; office work at 2–3 weeks; physical work at 4–6 weeks. Bowel function: 4–6 loose stools per day initially, settling to 1–2 formed stools within 4–8 weeks in most patients. First post-operative review at 2 weeks; pathology results discussed; adjuvant chemotherapy referral if Stage III. Full recovery — including return to sport and normal diet — by 6–8 weeks.

Rectal cancer arises in the last 15cm of the large bowel — defined anatomically as the bowel within the true bony pelvis below the peritoneal reflection. Treatment is substantially more complex than colon cancer due to the confined pelvic anatomy and proximity to the anal sphincter, bladder, and sexual nerve supply. Most locally advanced rectal cancers (Stage II–III on MRI) receive neoadjuvant chemoradiation before surgery — shrinking the tumour, reducing local recurrence risk, and occasionally enabling sphincter preservation for very low tumours. Surgery uses Total Mesorectal Excision (TME) — a specific sharp dissection technique critical for local disease control. Post-operative bowel function issues (LARS) are a significant quality-of-life consideration not applicable to colon cancer.

TME — introduced by Professor Bill Heald at Basingstoke in 1982 — is the surgical technique that transformed rectal cancer outcomes worldwide. It involves sharp dissection in the correct embryological fascial plane surrounding the mesorectum — removing the rectum as an intact, unbroken specimen package including all surrounding fat, blood vessels, and lymph nodes within their fascial envelope. Correct TME dissection preserves the autonomic nerve plexuses responsible for bladder and sexual function while achieving the clear circumferential margin that prevents local recurrence. Before TME became standard: local recurrence rates were 25–40%. With quality TME at specialist centres: local recurrence under 5%. Robotic surgery provides the visual clarity and instrument precision in the narrow pelvis necessary for consistently high-quality TME and reliable nerve preservation.

Neoadjuvant chemoradiation — combined chemotherapy (5-FU or capecitabine) and radiotherapy (45–50.4 Gy in 25–28 fractions) — is given before surgery for most locally advanced rectal cancers (Stage II–III on MRI, or MRI showing threatened circumferential resection margin). Benefits: reduces tumour size and T-stage, enabling R0 resection of previously borderline tumours; reduces local recurrence risk from 30% to under 10%; achieves pathological complete response (pCR) — no cancer in the surgical specimen — in 15–20% of patients; and in pCR patients, enables Watch and Wait (organ preservation) without surgery. Treatment takes 5–6 weeks; surgery or restaging assessment follows 8–12 weeks after completing chemoradiation to allow maximum tumour response.

Short-course radiotherapy (SCRT) delivers 25 Gy in 5 daily fractions over one week — followed by immediate surgery within 7–10 days (Swedish Rectal Cancer Trial) or delayed surgery after 4–8 weeks (Stockholm III trial, RAPIDO trial). SCRT achieves equivalent local recurrence rates to long-course chemoradiation for most locally advanced rectal cancers. Advantages over long-course CRT: shorter total treatment time (1 week vs 5–6 weeks); no systemic chemotherapy during radiation; and when delayed before surgery (4–8 weeks), achieves similar pCR rates. RAPIDO trial: SCRT followed by 18 weeks induction chemotherapy (CAPOX) then surgery achieves higher pCR rates (28%) with lower distant metastases than standard long-course CRT. SCRT is increasingly used as a convenient alternative, particularly when systemic treatment for metastatic disease is the priority.

LAR removes the rectum for cancer while preserving the anal sphincter — the colon is anastomosed to the anus or anal canal restoring bowel continuity through a single-stage or two-stage operation. A temporary loop ileostomy is created to protect the anastomosis during healing and is reversed at 8–12 weeks after X-ray confirmation of healing. LAR is the standard operation for mid and low rectal cancers where adequate oncological margins can be achieved while preserving the sphincter. Robotic LAR achieves sphincter preservation in a significantly higher proportion of patients than open surgery — particularly in male patients with a narrow bony pelvis where instrument access is most limited. Most patients with rectal cancer can avoid a permanent stoma with current robotic surgical techniques at specialist centres.

APR removes the rectum, anus, and entire anal sphincter complex — through both an abdominal and a perineal incision — creating a permanent sigmoid colostomy. APR is required when: the tumour directly invades the sphincter complex with no oncological possibility of clear margin preservation; the tumour is at or below the dentate line with no functional sphincter to preserve; or severe pre-existing faecal incontinence makes sphincter preservation clinically meaningless even if technically feasible. Robotic ELAPE (Extralevator APR) — a wider cylindrical resection removing the levator muscles en bloc with the specimen — achieves lower positive CRM rates than conventional APR. Patients considering APR should seek a second opinion at a specialist robotic rectal cancer centre before accepting a permanent colostomy recommendation.

Sphincter preservation is the goal of modern rectal cancer surgery — achieving cancer cure while keeping the anal sphincter complex intact and functional, avoiding permanent stoma. Key strategies enabling sphincter preservation: neoadjuvant chemoradiation shrinks low rectal tumours and reduces T-stage — downstaging many tumours sufficiently to allow sphincter-preserving resection; robotic TME in the narrow pelvis allows precise dissection within millimetres of the sphincter under 10x 3D magnification; and intersphincteric resection (ISR) removes the internal sphincter alone while preserving the external sphincter, enabling coloanal anastomosis in very low tumours. Sphincter preservation is NOT always possible — when the tumour directly invades the external sphincter or puborectalis, APR is oncologically required. Specialist review is essential before accepting any permanent colostomy recommendation.

ISR is a sphincter-preserving technique for very low rectal cancers — tumours within 1–3cm of the dentate line — that would otherwise require APR. The internal anal sphincter (the involuntary sphincter muscle layer) is removed together with the rectum, while the external sphincter (the voluntary muscle controlling continence) is preserved. The colon is then anastomosed to the dentate line or anal canal — a coloanal anastomosis. ISR is technically demanding and requires meticulous patient selection: the external sphincter must be uninvolved and the patient must have adequate pre-operative sphincter function. Post-operative bowel function after ISR is demanding — frequent stools and urgency are common (severe LARS), requiring intensive rehabilitation. Pre-operative biofeedback and physiotherapy assessment helps predict functional outcomes and counsel patients realistically.

Watch and Wait — also called Organ Preservation or Non-Operative Management — is a management strategy for rectal cancer patients achieving complete clinical response (cCR) after neoadjuvant chemoradiation: no detectable tumour on digital rectal examination, pelvic MRI, and flexible sigmoidoscopy. Instead of proceeding to TME surgery, these patients enter intensive surveillance: clinical examination and MRI every 3 months for 2 years, then 6-monthly. The Habr-Gama group pioneered Watch and Wait — 10-year data from Sao Paulo show local regrowth in 15–25% of cCR patients, and most regrowths detected on surveillance can be salvaged by surgery. Watch and Wait avoids major pelvic surgery and a temporary or permanent stoma. It requires specialist centre assessment, confirmed complete response, and committed long-term surveillance — not suitable at all hospital settings.

Pathological complete response (pCR) means no viable cancer cells are found in the surgical specimen after neoadjuvant chemoradiation — only fibrosis and scar tissue replacing the tumour. pCR is achieved in 15–20% of patients after standard long-course chemoradiation and in 25–30% after intensified neoadjuvant regimens (RAPIDO, UNICANCER PRODIGE trial). Significance of pCR: patients who achieve pCR have excellent long-term prognosis — 5-year disease-free survival approaching 85–90%; they may be candidates for Watch and Wait (avoiding surgery altogether); and pCR is increasingly used as a surrogate endpoint in trials evaluating intensified neoadjuvant regimens. The OPRA trial demonstrated that adding consolidation chemotherapy (FOLFOX or CAPOX) after standard chemoradiation increases pCR rates from 20% to 36%, enabling Watch and Wait in more patients.

LARS — Low Anterior Resection Syndrome — is a cluster of bowel dysfunction symptoms affecting patients after sphincter-preserving rectal cancer surgery: frequent bowel movements (10–20 daily initially), urgency (inability to defer defecation), clustering (several movements in a short period), incomplete evacuation (persistent sensation of needing to defecate), and incontinence (leakage of stool or gas). LARS affects 40–60% of LAR patients to some degree; severe LARS significantly impacts quality of life, social function, and return to work. Factors predicting severe LARS: low anastomosis (closer to anal verge); pelvic radiation before surgery; covering ileostomy reversal. LARS is not permanent — it improves significantly over 12–24 months. Comprehensive management: diet, loperamide, physiotherapy, biofeedback, transanal irrigation, and in severe cases, sacral nerve stimulation.

Transanal irrigation (TAI) is a technique where water is introduced into the rectum or neorectum via a catheter or cone device — flushing out bowel contents on demand and providing a period of predictable continence. TAI is highly effective for severe LARS — achieving bowel emptying at a chosen time and reducing the urgency and frequency of unpredicted bowel movements that severely disrupt daily life. The device (Peristeen, Qufora, or similar) is used once or twice daily — initially with nurse instruction. TAI is also effective for: neurogenic bowel dysfunction; descending perineum syndrome; and selected patients with faecal incontinence. Most patients with severe LARS who persist with TAI achieve significantly better quality of life — the technique requires commitment and practice before benefits are fully realised. A dedicated stoma/continence nurse provides training and ongoing support.

Biofeedback is a physiotherapy technique that retrains the pelvic floor and external anal sphincter using real-time feedback from anorectal manometry or EMG sensors — teaching the patient to squeeze and relax the pelvic floor muscles correctly. For LARS patients: biofeedback improves sphincter coordination and rectal sensory threshold; it is most effective when combined with dietary modification, loperamide, and transanal irrigation in a comprehensive bowel rehabilitation programme. For pre-operative ISR patients: biofeedback before surgery optimises baseline sphincter function, predicting post-operative functional outcomes and improving post-operative rehabilitation speed. Pelvic floor physiotherapy including biofeedback is a standard component of Dr. Gore's post-operative rehabilitation programme for all low rectal cancer patients at Silver Leaf Clinic, Hadapsar, Pune.

Lateral pelvic lymph node dissection (LPND) removes lymph nodes from the lateral pelvic sidewall — the obturator fossa, internal iliac, and external iliac groups — in addition to standard TME. LPND is standard practice in Japan for rectal cancers below the peritoneal reflection with lateral node involvement on MRI. In Western practice, lateral nodes are treated with neoadjuvant chemoradiation rather than surgical dissection — with equivalent local control rates in MRI-negative lateral nodes. For MRI-positive lateral nodes that fail to downstage after chemoradiation, LPND reduces lateral pelvic recurrence rates significantly. LPND adds 1–2 hours to the TME procedure and carries risks of bladder dysfunction, sexual dysfunction, and lymphocele — benefits must outweigh risks in each individual patient after MDT review.

The circumferential resection margin (CRM) is the non-peritonealised radial margin of the surgical specimen — the radial distance between the outermost extent of the tumour (or involved lymph nodes or mesorectal deposits) and the cut surface of the specimen. CRM positivity — defined as tumour within 1mm of the circumferential margin — is the single strongest predictor of local recurrence and survival in rectal cancer. CRM positivity rate is a key quality indicator for rectal cancer surgery — specialist robotic TME centres achieve CRM positivity rates under 5%; inadequate surgery results in rates of 15–30%. MRI pre-operatively predicts threatened CRM — guiding the decision on neoadjuvant treatment and the exact surgical plane of dissection. A quality TME specimen with CRM negativity is the definitive proof of adequate rectal cancer surgery.

Sacral nerve stimulation (SNS) — also called sacral neuromodulation — delivers low-level electrical impulses to the sacral nerve roots (S3) via a permanently implanted electrode and pulse generator — modulating bowel and bladder function. SNS is effective for: severe LARS with faecal incontinence refractory to dietary modification, loperamide, biofeedback, and transanal irrigation; idiopathic faecal incontinence; and urinary incontinence or urgency frequency. The procedure: trial phase (2 weeks with external pulse generator — the patient assesses benefit); permanent implantation of the device if more than 50% improvement in symptoms. SNS is reversible — the device can be removed or adjusted. Approximately 70% of carefully selected LARS and incontinence patients achieve significant, durable improvement with SNS. A specialist pelvic floor surgeon or colorectal surgeon with SNS experience performs the implantation.

A defunctioning loop ileostomy is a temporary stoma — created at the time of low anterior resection — to protect the anastomosis (the bowel join) during healing. The loop of small bowel is brought to the surface through a separate port site incision; one limb is opened as a functioning stoma that diverts all intestinal content away from the anastomosis; the other limb leads to the distal bowel and anastomosis. The ileostomy is reversed (closed) at 8–12 weeks after confirming anastomosis healing on gastrografin enema or flexible sigmoidoscopy. The defunctioning ileostomy does not prevent anastomotic leakage — but it dramatically reduces its clinical consequences by diverting faeces away from the leaking anastomosis, allowing conservative management rather than emergency re-operation in most cases.

Total Neoadjuvant Therapy (TNT) delivers all systemic chemotherapy before surgery — combining both chemoradiation and systemic chemotherapy in the pre-operative period — rather than reserving adjuvant chemotherapy for after surgery. Rationale: earlier treatment of micrometastatic disease; higher rates of pCR enabling Watch and Wait; and better chemotherapy compliance (tolerability is better before major surgery). Key TNT regimens: RAPIDO trial (short-course RT + CAPOX or FOLFOX chemotherapy + surgery) — achieves 28% pCR and lower distant metastases; PRODIGE 23 (induction FOLFIRINOX + long-course CRT + surgery) — achieves 27.5% pCR and improved disease-free survival. TNT is increasingly the standard approach for locally advanced rectal cancer at specialist centres — moving patients toward Watch and Wait and reducing distant recurrence.

Robotic ISR performs the intersphincteric dissection — separating the internal from the external sphincter — under 10x 3D magnification, providing visualisation of the sphincter planes not achievable in open or standard laparoscopic surgery. The robotic approach allows precise, tremor-free dissection within the narrow intersphincteric groove, minimising inadvertent external sphincter injury that would compromise continence. The coloanal anastomosis is then completed transanally. Dr. Gore performs robotic ISR for selected very low rectal cancers at Sahyadri Manipal Hospital, Pune — enabling avoidance of APR and permanent stoma in appropriately selected patients. Detailed pre-operative patient counselling regarding expected bowel function (severe LARS initially, improving over 12–24 months) is essential before proceeding to ISR.

MRI Tumour Regression Grade (mrTRG) is a validated radiological scoring system assessing the degree of tumour fibrosis and response to neoadjuvant treatment on restaging MRI (performed 6–8 weeks after completing chemoradiation). mrTRG score 1–2 indicates near-complete or complete MRI response — correlating with pathological complete response and suitability for Watch and Wait. mrTRG 3 indicates intermediate response — requires careful clinical correlation before Watch and Wait can be considered. mrTRG 4–5 indicates poor response — proceed to surgery. Restaging MRI is essential before making any decision about Watch and Wait — a clinical examination alone is insufficient to assess response safely. High-quality 3 Tesla pelvic MRI at a centre experienced in rectal cancer MRI reporting is required for reliable mrTRG assessment.

Yes — local recurrence (tumour returning in the pelvis at the site of the original resection) occurs in 5–10% of patients after quality TME surgery, and in up to 20–30% after inadequate surgery. Local recurrence from rectal cancer is one of the most challenging oncological situations — causing severe pelvic pain, bleeding, and obstruction. Treatment: multimodal reassessment at a specialist pelvic MDT; salvage surgery (pelvic exenteration — radical removal of the rectum, bladder, and/or uterus) achieves R0 resection in selected patients with 30–40% five-year survival; re-irradiation (EBRT or brachytherapy) for previously unirradiated patients; or palliative systemic therapy for unresectable recurrence. Preventing local recurrence through quality primary TME is infinitely preferable — specialist robotic rectal cancer surgery at high-volume centres achieves local recurrence rates under 5%.

Pelvic exenteration is the most radical pelvic cancer operation — removing the rectum with all or part of the pelvic organs (bladder, prostate, uterus, ovaries, vagina) as a single en bloc specimen, often with perineal resection and pelvic floor reconstruction. It is performed for: locally advanced primary rectal cancer invading adjacent pelvic organs (T4b); locally recurrent rectal cancer after prior TME; and selected gynaecological cancers invading the rectum. R0 pelvic exenteration achieves 5-year survival of 35–55% in carefully selected patients — offering the only potentially curative treatment for these technically challenging cases. Pelvic exenteration is performed at highly specialist centres by a team including colorectal, urological, and gynaecological surgeons. Reconstruction requires complex plastic surgical expertise — VRAM flap, ileal conduit or neobladder, colostomy.

A coloanal anastomosis (CAA) connects the descending or sigmoid colon directly to the dentate line or lower anal canal — after removing the entire rectum and internal sphincter. It is performed after ultra-low anterior resection or intersphincteric resection for very low rectal cancers. A J-pouch (small reservoir constructed from 5–6cm of folded colon) or a coloplasty (longitudinal colotomy closed transversely creating a slight reservoir) is sometimes added to reduce early bowel frequency. A protective loop ileostomy is mandatory for coloanal anastomosis — allowing the anastomosis to heal for 12 weeks before reversal. CAA is the alternative to APR for very low rectal cancer — it achieves cancer clearance while avoiding a permanent colostomy. Post-operative functional counselling is essential: early frequent bowel movements improve markedly over 12–18 months.

Recovery after robotic LAR follows ERAS protocols. Day of surgery: mobilisation sitting out of bed; drinking water 4 hours post-operatively. Day 1: Walking in the ward; light diet; urinary catheter usually remains for 5–7 days (pelvic surgery risks urinary retention). Day 2–3: Progressing to normal diet; physiotherapy; bowel sounds returning. Hospital stay: 4–7 days for robotic LAR. Home recovery: light activities from week 1; driving after 3–4 weeks; office work 3–4 weeks; physical work 6–8 weeks. Stoma care: ileostomy care nurse teaching before discharge; reversal planned at 8–12 weeks. After reversal: bowel function is frequently erratic for 3–6 months (LARS) — managed with diet modification, loperamide, and pelvic floor physiotherapy. First oncology review at 4 weeks; adjuvant chemotherapy referral if indicated.

Both procedures remove the rectum while preserving the sphincter — the key difference is the level of the anastomosis. High anterior resection (HAR): anastomosis above 10cm from the anal verge — for upper rectal and rectosigmoid junction cancers; LARS is uncommon as the upper rectum functions more like colon. Low anterior resection (LAR): anastomosis at 5–10cm from the anal verge — for mid-rectal cancers; LARS is common and requires active management. Ultra-low anterior resection (ULAR): anastomosis below 5cm from the anal verge — for low rectal cancers; severe LARS is expected; protective ileostomy is mandatory; sexual and bladder function at greatest risk from nerve dissection in the very low pelvis. Robotic surgery is most beneficial — and most critical — for LAR and ULAR where instrument dexterity in the confined deep pelvis determines both oncological and functional outcomes.

A stoma is a surgically created opening in the abdominal wall through which the bowel diverts and empties into a sealed bag worn on the body. Two main types relevant to colorectal cancer: ileostomy — opening from the small bowel (ileum); output is liquid to porridge consistency, high volume (1–1.5 litres per day), and requires careful hydration management. Colostomy — opening from the large bowel (colon); output is more formed, closer to normal stool consistency, and lower volume (1–2 times daily in most cases). After rectal cancer surgery: most patients have a temporary loop ileostomy protecting the anastomosis — reversed at 8–12 weeks. APR surgery creates a permanent end colostomy — when the rectum and sphincter are removed and cannot be reconnected.

No — and this is the most important reassurance for patients facing rectal cancer surgery. The vast majority of patients undergoing rectal cancer surgery (LAR, ISR, ultra-low AR) have a temporary loop ileostomy — created to protect the anastomosis during healing and reversed at 8–12 weeks. A permanent colostomy is only created after APR surgery — when the tumour directly invades the sphincter making sphincter preservation oncologically impossible. At experienced robotic rectal cancer centres, fewer than 15–20% of rectal cancer patients require permanent colostomy. Before accepting a permanent stoma recommendation, patients should seek a specialist second opinion — robotic surgery enables sphincter preservation in many patients told they need an APR at less experienced centres. Call 88558 10010 for a second opinion consultation.

Bag changing is a learnable skill that most patients master within 5–6 changes. Step 1: Gather everything before starting — clean bag (correctly sized), disposal bag, damp cloth or wipes (fragrance-free, no moisturiser), and skin barrier paste if prescribed. Step 2: Empty the current bag if more than one-third full — reducing mess and weight. Step 3: Peel the old bag away gently from top to bottom, supporting the skin with one hand. Step 4: Clean the stoma and surrounding skin with warm water; avoid soap with moisturiser — it prevents adhesion. Step 5: Pat completely dry — the bag only adheres to dry skin. Step 6: Measure the stoma and cut the bag opening 2–3mm larger. Step 7: Apply skin barrier paste if prescribed. Step 8: Press the new bag firmly onto skin for 30–60 seconds with warm hands. Step 9: Dispose of the old bag in a sealed disposal bag (household waste — not recycling).

Most modern pouching systems last 2–3 days — changed before leakage occurs rather than waiting until the bag fails. Changing before the seal breaks prevents peristomal skin damage, which is the most common and preventable stoma complication. The best time to change: before meals and before drinking, when output is least active — typically morning. Two-piece systems (separate baseplate and bag) allow the bag to be emptied and replaced without removing the baseplate — the baseplate can remain for 3–5 days. For ileostomy patients with high output: empty the bag when it is one-third full (never more than half full) — a heavy bag pulls on the flange and risks leakage. Bag lifespan varies by brand — a stoma nurse helps identify the optimal system for each patient's stoma shape, skin type, and activity level.

Peristomal skin — the skin immediately around the stoma — must be protected from leakage and irritation. Healthy peristomal skin is exactly the same colour and texture as the surrounding abdomen. Red, sore, or broken skin indicates leakage under the flange, incorrect bag sizing, or adhesive sensitivity. Prevention: ensure the bag opening is cut correctly (2–3mm larger than the stoma, no more); use a skin barrier paste or protective ring to fill any uneven skin contours around the stoma; change the bag regularly before leakage occurs; dry the skin thoroughly before applying the new flange; avoid products with oil, fragrance, or moisturiser near the stoma. If peristomal skin breaks down: contact the stoma nurse immediately — specialist barrier wipes, protective rings, and convex flanges resolve most skin problems quickly when addressed early.

Diet with an ileostomy requires careful management in the first 6 weeks while the bowel adapts. Foods safe to start: white rice, white bread, boiled potato, pasta, eggs, boiled chicken and fish, banana, cooked vegetables without skin. Avoid in the first 6 weeks: raw vegetables, nuts, seeds, corn, dried fruit, mushrooms, peas — these can cause blockage at the narrow ileostomy aperture. Foods that increase output (use with caution): fruit juice, spicy food, alcohol, coffee, high-fibre foods. Foods that help thicken ileostomy output: banana, white rice, boiled potato, white bread, pasta, marshmallows. Chew all food thoroughly — poorly chewed fibrous food is the most common cause of early stoma blockage. From 6 weeks: gradually introduce new foods one at a time, waiting 24–48 hours to assess the effect. Long-term diet after ileostomy is largely unrestricted with experience.

Dehydration is the single most common and preventable complication of ileostomy — the small bowel reabsorbs far less water than the colon, so ileostomy output is naturally high volume (1–1.5 litres per day). Minimum fluid intake: 2–2.5 litres daily. Include oral rehydration solution (ORS) — St. Mark's recipe: 1 litre water, 6 level teaspoons sugar, 1 level teaspoon salt — if output exceeds 1.5 litres per day. Signs of dehydration: dark urine (normal is pale straw yellow), reduced urine output, dizziness, headache, muscle cramps, and confusion. Go to the emergency department immediately if: output exceeds 2 litres in 24 hours; you cannot keep fluids down due to vomiting; or you develop signs of severe dehydration (no urine output, rapid heart rate, confusion). High-output ileostomy (above 1.5 litres) may require loperamide, codeine phosphate, or hospital admission for IV fluids.

Ileostomy blockage (food bolus obstruction) occurs when incompletely chewed or high-fibre food blocks the narrow stoma aperture — causing abdominal pain, bloating, no output from the stoma, and nausea. Common culprits: mushrooms, nuts, corn, dried fruit, raw vegetables, and apple skins. Initial management at home: stop eating solid food; drink warm fluids; gently massage the abdomen; lie with knees drawn up and rock gently; and try a warm bath (the warmth can relax the stoma and allow the blockage to pass). If no output for 4–6 hours with increasing abdominal pain and distension: go to the emergency department immediately — a complete blockage may require hospital intervention. Prevention: chew all food thoroughly (30 chews per mouthful); introduce high-fibre foods slowly; stay well hydrated. The stoma nurse should be contacted for any blockage not resolving within 2 hours.

Yes — a stoma does not prevent any of these activities. Swimming: stoma bags are waterproof and swimming-specific mini-bags or caps are available from stoma suppliers. Swimming is safe from week 6 once the wound is fully healed. Exercise and sport: light walking from week 2; gym and sport from 8–12 weeks once abdominal muscle healing is confirmed; contact sports require a protective stoma guard. Travel: take double the expected supply of bags (airlines occasionally lose luggage); carry a letter from your surgeon explaining the stoma; keep supplies in hand luggage; research hospital locations at your destination; and declare the stoma to travel insurance. Clothing: modern stoma bags are discreet under clothing; high-waisted underwear and briefs support the bag; stoma wraps and belts provide extra security during sport. There is no sport or activity categorically prevented by a stoma — with correct equipment and preparation.

A stoma does not prevent intimacy — but it requires adjustment, communication, and time. Practical strategies: empty and secure the bag before intimacy; use a smaller intimate pouch or stoma cap that covers the stoma without a hanging bag; a stoma wrap or belt holds the bag flat and discreet against the body; and opaque beige or skin-coloured bags are available for discretion. Allow 6–8 weeks of physical recovery before resuming intimacy — the abdominal wound and pelvic structures need time to heal. Sexual dysfunction after rectal cancer surgery — particularly erectile dysfunction in men and dyspareunia or vaginal dryness in women — may occur from nerve changes in the pelvis during TME; this is separate from the stoma itself and should be discussed specifically with Dr. Gore at post-operative follow-up. Specialist psychosexual counselling is highly effective and available.

A parastomal hernia is a bulge of abdominal contents through the weakened abdominal wall around the stoma — the most common long-term stoma complication, affecting 30–50% of permanent colostomy patients within 5 years. It appears as a visible bulge around the stoma — worsened by straining, coughing, and upright posture; relieved by lying flat. Prevention: support belt or corset worn from the time of stoma formation — greatly reduces parastomal hernia risk; avoid lifting more than 5kg in the first 3 months; maintain healthy body weight. Management: minor hernia — stoma support belt and activity modification; large or symptomatic hernia causing pouch seal failure, pain, or obstruction risk — surgical repair (suture repair, mesh repair, or stoma relocation). Mesh repair carries the lowest recurrence rate but the highest infection risk. Discuss any bulge around the stoma with Dr. Gore's team promptly.

Stoma reversal (loop ileostomy closure) restores bowel continuity — performed after confirming the anastomosis has healed on gastrografin enema or flexible sigmoidoscopy at 8 weeks, and after completing any planned adjuvant chemotherapy (chemotherapy impairs anastomotic healing and reversal is delayed until chemotherapy is complete). The operation: laparoscopic or open — the stoma loop is freed from the abdominal wall, the two limbs are joined (anastomosed), and bowel returned to the abdomen. Takes 1–2 hours. Hospital stay 3–5 days. After reversal: bowel function is initially erratic — frequent loose stools (LARS) expected. Not all stomas can be reversed — anastomotic leak with stricture, tumour recurrence, or patient fitness concerns may prevent reversal. Eligibility for reversal is reviewed and discussed at every post-operative follow-up appointment at Silver Leaf Clinic.

Seek emergency care immediately if: stoma colour changes from bright pink to dark purple, brown, or black — possible ischaemia (blood supply failure); stoma completely retracts below the skin surface — retraction; stoma suddenly prolapses (extends outward by more than 2–3cm); no output from ileostomy for more than 4–6 hours with abdominal pain and distension — possible blockage; output exceeds 2 litres in 24 hours with signs of dehydration; bright red bleeding from the stoma that does not stop with gentle pressure; fever above 38.5°C with stoma site pain or discharge; or severe abdominal pain. Minor bleeding during bag change (from surface of the stoma) is normal — the stoma has many small blood vessels and bleeds easily on contact. Call 88558 10010 or WhatsApp 84118 08284 immediately for any of the emergency signs above.

Adjustment to a stoma — particularly a permanent colostomy — involves a recognised psychological process including grief for the pre-stoma body, fear of leakage, embarrassment, and changes to body image and self-esteem. These responses are normal and do not mean they will persist. Depression after stoma surgery affects approximately 1 in 4 patients in the first 3 months — this is a medical condition, not a weakness, and effective treatment is available. Resources: the stoma nurse at Sahyadri Manipal Hospital provides one-to-one support and answers practical questions during and after admission; peer support — speaking to someone who has lived comfortably with a stoma for years — is enormously valuable; the Indian Ostomy Association provides community support and practical guidance. If dark thoughts or persistent low mood persist beyond 4 weeks, please speak with Dr. Gore's team — psychological referral and treatment are arranged promptly.

Long-term quality of life with a permanent colostomy is excellent for the vast majority of patients — though adjustment takes time. Research consistently shows that colostomy patients report quality of life equivalent to age-matched populations without cancer by 12–24 months after surgery. The stoma is managed with a routine that becomes second nature — most experienced colostomy patients spend under 5 minutes on bag management per day. People with permanent colostomies work full-time, exercise, swim, travel internationally, maintain relationships, and lead completely active lives. Famous athletes, professionals, and public figures have lived and excelled with colostomies. The stoma represents surviving colorectal cancer — it is not a disability. Long-term annual stoma nurse review is recommended — stoma size and shape may change with age or weight change, and the bag system may need adjustment.

Gastric cancer arises from the stomach lining — most commonly as adenocarcinoma. Risk factors: Helicobacter pylori infection (the most important modifiable risk factor — causes chronic gastritis progressing to intestinal metaplasia and cancer over 20–30 years); smoking; dietary factors (high salt, preserved meats, low fruit and vegetable intake); atrophic gastritis; pernicious anaemia; and hereditary diffuse gastric cancer (CDH1 mutation — E-cadherin). In India, gastric cancer incidence varies significantly by region — higher in southern and northeastern India. Diffuse-type gastric cancer (signet ring cell, peritoneal spread) has worse prognosis than intestinal-type. H. pylori eradication significantly reduces gastric cancer risk in infected individuals — all first-degree relatives of gastric cancer patients should be tested and treated.

Gastric cancer symptoms are often non-specific in early disease — explaining why most patients present at advanced stage. Warning signs: unexplained significant weight loss (most common symptom); early satiety — feeling full after eating small amounts; epigastric pain or discomfort; dysphagia (difficulty swallowing) — suggests proximal stomach or gastroesophageal junction cancer; nausea or vomiting; iron deficiency anaemia from slow bleeding; palpable epigastric mass in advanced disease; left supraclavicular lymph node (Virchow's node) — a classic sign of advanced gastric cancer. Any adult with persistent dyspepsia lasting more than 4 weeks, particularly above age 55, must have urgent upper GI endoscopy (OGD) — 'alarm' symptoms (weight loss, dysphagia, anaemia, vomiting) require OGD within 2 weeks regardless of age.

Gastrectomy removes all or part of the stomach for gastric cancer. Distal gastrectomy removes the lower two-thirds of the stomach — for antral and pyloric tumours; reconstruction uses Billroth II or Roux-en-Y gastrojejunostomy. Total gastrectomy removes the entire stomach — for body, fundus, or diffuse-type tumours; reconstruction uses Roux-en-Y oesophagojejunostomy. D2 lymph node dissection — removing the first and second tier of perigastric and coeliac axis lymph nodes — is the international quality standard for curative gastric cancer surgery. Staging laparoscopy is performed before definitive resection to exclude peritoneal deposits not visible on CT — changing management in 15–30% of cases. FLOT neoadjuvant chemotherapy is given before surgery for Stage II–III gastric cancer.

FLOT — 5-FU, leucovorin, oxaliplatin, docetaxel — is the current standard neoadjuvant and adjuvant chemotherapy regimen for resectable gastric and gastroesophageal junction (GEJ) cancer — established by the FLOT4 trial (NEJM 2019). Protocol: 4 cycles FLOT before surgery (neoadjuvant) + 4 cycles after surgery (adjuvant). The FLOT4 trial demonstrated FLOT achieves median overall survival of 50 months versus 35 months for the previous ECF regimen — a landmark improvement in gastric cancer treatment. Pathological complete response after FLOT: 15–17%. FLOT is more intensive than ECF — patients need adequate performance status (ECOG 0–1), good renal and cardiac function, and close monitoring for neurotoxicity (oxaliplatin neuropathy) and haematological toxicity (docetaxel). Not all patients tolerate all 8 cycles — dose modifications are made at oncology review.

Staging laparoscopy is a brief keyhole procedure under general anaesthesia — recommended for all locally advanced gastric cancer (T3/T4 on CT) before definitive surgery or neoadjuvant chemotherapy. The surgeon inspects the peritoneal cavity, liver surface, and omental surfaces — detecting peritoneal deposits, liver nodules, and omental seeding not visible on CT. Peritoneal washing cytology is collected simultaneously — positive cytology alone (without visible deposits) upstages the patient to Stage IV, changing management from curative surgery to systemic chemotherapy. Staging laparoscopy identifies occult peritoneal disease in 15–30% of patients deemed resectable on CT. A 30–45 minute procedure with disproportionately high clinical value — preventing unnecessary major laparotomy in patients with occult peritoneal disease.

Gastric cancer lymph node dissection is classified by the nodal groups removed. D1 dissection removes only the immediately perigastric lymph nodes (Stations 1–6 for total gastrectomy). D2 dissection additionally removes the second tier nodes along the coeliac axis — hepatic artery, left gastric artery, splenic artery, and coeliac trunk nodes (Stations 7–12). D2 is the international gold standard for curative gastric cancer surgery — established by Dutch D1 vs D2 trial long-term results (15-year follow-up: D2 achieves lower gastric cancer-related death rate). D1 is inadequate for cancer surgery — results in understaging and inadequate nodal clearance. The suprapancreatic nodal dissection of D2 is technically demanding — the robotic approach provides superior 3D magnification during dissection of these deep nodes adjacent to the pancreatic head and portal vein.

HER2 positivity (IHC 3+ or IHC 2+ confirmed by FISH) occurs in approximately 15–20% of gastric and GEJ adenocarcinomas. HER2-positive gastric cancer is treated with trastuzumab (Herceptin) added to first-line systemic chemotherapy (capecitabine or 5-FU plus oxaliplatin or cisplatin) — the ToGA trial demonstrated a median overall survival improvement from 11.1 to 13.8 months with trastuzumab addition. For HER2-positive metastatic gastric cancer, pembrolizumab (anti-PD-1) plus trastuzumab plus chemotherapy (KEYNOTE-811 trial) achieves 73% objective response rate — the most effective first-line regimen currently available. HER2 testing by IHC on the biopsy specimen is now mandatory at diagnosis for all gastric and GEJ cancer patients — it directly determines systemic treatment choice.

Oesophageal cancer — cancer of the food pipe — occurs as two main histological types with different biology, location, and management. Squamous cell carcinoma (SCC): most common type globally and in India; arises in the mid and upper oesophagus; strongly linked to smoking, alcohol, and hot beverage consumption; high sensitivity to chemoradiation (CROSS protocol achieves 49% pCR). Adenocarcinoma: most common type in Western countries; arises in the lower oesophagus and GEJ; strongly linked to Barrett's oesophagus (a consequence of chronic GERD — acid reflux); closely related to gastric adenocarcinoma in management. Both types are diagnosed by upper GI endoscopy with biopsy and staged with CT, PET-CT, and EUS (endoscopic ultrasound for T and N staging).

Barrett's oesophagus is a pre-malignant condition where the normal squamous lining of the lower oesophagus is replaced by specialised intestinal metaplasia — columnar epithelium with goblet cells — as a consequence of chronic gastroesophageal reflux disease (GERD). Barrett's oesophagus confers an annual risk of oesophageal adenocarcinoma of approximately 0.3–0.5% per year — 30–40 times higher than the general population. Surveillance endoscopy: every 2–5 years for Barrett's without dysplasia; every 6–12 months for low-grade dysplasia; every 3 months for high-grade dysplasia with consideration for endoscopic treatment (radiofrequency ablation, endoscopic mucosal resection). High-grade dysplasia or intramucosal cancer in Barrett's is treated endoscopically — EMR (endoscopic mucosal resection) or radiofrequency ablation — avoiding oesophagectomy in most cases.

RAMIE — Robotic Assisted Minimally Invasive Esophagectomy — is a two-phase operation for oesophageal cancer: robotic thoracoscopic dissection of the oesophagus and mediastinal lymph nodes in the chest, followed by robotic abdominal mobilisation of the stomach and fashioning of a gastric conduit. The conduit is pulled into the chest (or neck) and anastomosed to the remaining upper oesophagus. ICG fluorescence intraoperatively confirms blood supply to the conduit tip before anastomosis — preventing conduit tip ischaemia, the most feared post-operative complication causing anastomotic breakdown. RAMIE achieves lower pulmonary complication rates and shorter ICU stay than open thoracotomy. CROSS neoadjuvant chemoradiation is the standard pre-operative treatment before RAMIE for Stage II–III oesophageal cancer.

CROSS — ChemoRadiation for Oesophageal cancer followed by Surgery Study (NEJM 2012) — is the established neoadjuvant treatment before esophagectomy. Protocol: weekly carboplatin (AUC 2) plus paclitaxel (50 mg/m²) for 5 cycles concurrent with 41.4 Gy radiotherapy in 23 fractions — administered over 5 weeks. Results: pathological complete response in 49% of squamous cell carcinoma and 23% of adenocarcinoma; overall survival improved from 24 to 49 months versus surgery alone — a landmark improvement. CROSS is the international standard pre-operative treatment before esophagectomy for Stage II–III oesophageal cancer. After CROSS, restaging CT and PET-CT are performed — esophagectomy proceeds 6–8 weeks after completing chemoradiation. In cases achieving near-complete or complete clinical response after CROSS, Watch and Wait is being explored in clinical trials.

Oesophageal cancer symptoms: progressive dysphagia — difficulty swallowing starting with solids then progressing to liquids — is the most characteristic symptom (any progressive difficulty swallowing must be investigated urgently with OGD within 2 weeks). Significant unexplained weight loss — from reduced calorie intake due to dysphagia. Odynophagia — pain on swallowing. Regurgitation of undigested food. Hoarseness — from recurrent laryngeal nerve involvement by upper mediastinal tumour. Chronic cough — from aspiration or tracheo-oesophageal fistula. Haematemesis — vomiting blood from tumour bleeding. Chest or back pain — in locally advanced disease. Any adult with progressive dysphagia must have urgent upper GI endoscopy — this symptom should never be attributed to reflux or anxiety without endoscopic exclusion of cancer.

EMR is a minimally invasive endoscopic technique that removes early-stage GI cancers — confined to the mucosa or superficial submucosa — without surgery. Technique: saline is injected under the lesion to lift it away from the underlying muscle; a snare is passed around the raised lesion and current applied to remove it as one piece (en bloc). Applications: early oesophageal cancer (T1a) in Barrett's oesophagus; early gastric cancer (EGC) — mucosal cancer under 2cm without ulceration; large colorectal polyps — including flat and sessile serrated lesions. ESD (Endoscopic Submucosal Dissection) allows larger, en bloc resection of lesions not amenable to standard EMR — using specialised knives to dissect directly in the submucosal plane. Successful EMR or ESD avoids the morbidity of major surgery — with equivalent cure rates for carefully selected T1a lesions.

GEJ cancer arises at the junction of the oesophagus and stomach — classified by Siewert classification: Type I — distal oesophagus cancer (5–1cm above the gastric cardia); Type II — true cardia cancer (1cm above to 2cm below the cardia); Type III — subcardial gastric cancer (2–5cm below the cardia). Siewert Type I: managed as oesophageal cancer — CROSS neoadjuvant + Ivor Lewis esophagectomy. Siewert Type II: managed as either oesophageal or gastric cancer depending on centre expertise — CROSS or FLOT neoadjuvant; esophagectomy or total gastrectomy. Siewert Type III: managed as gastric cancer — FLOT neoadjuvant + total gastrectomy with D2 dissection. HER2 testing mandatory for all GEJ adenocarcinoma — determining trastuzumab eligibility for metastatic disease.

EUS (Endoscopic Ultrasound) uses a high-frequency ultrasound probe on the tip of an endoscope to image the wall layers of the oesophagus or stomach from the inside — providing the most accurate T-staging (depth of tumour invasion into the bowel wall) and N-staging (lymph node size and characteristics) available for upper GI cancers. EUS accurately distinguishes T1 (mucosal/submucosal) from T2 (muscularis propria) cancer — critical for deciding between endoscopic resection (T1a) and surgery (T2+). EUS-FNA (fine needle aspiration) samples suspicious lymph nodes under real-time ultrasound guidance — confirming nodal metastasis before treatment planning. EUS is most valuable for early-stage tumours where precise T-staging determines whether endoscopic or surgical management is appropriate.

The Siewert classification categorises tumours at the gastroesophageal junction (GEJ) by their epicentre relative to the anatomical GEJ. Type I: epicentre 5–1cm above the GEJ — distal oesophageal adenocarcinoma, usually arising in Barrett's oesophagus. Type II: epicentre 1cm above to 2cm below the GEJ — true cardia cancer; oncologically and surgically distinct from both oesophageal and gastric cancer. Type III: epicentre 2–5cm below the GEJ — subcardial gastric cancer. The Siewert type determines the surgical approach: Type I requires oesophagectomy with gastric conduit reconstruction; Type III requires total gastrectomy; Type II can be treated by either, depending on tumour extent and centre expertise. The MDT classification of GEJ cancer as Siewert Type I, II, or III directly determines neoadjuvant treatment choice (CROSS vs FLOT) and surgical approach.

Gastric GIST (Gastrointestinal Stromal Tumour) arises from the interstitial cells of Cajal in the stomach wall — not from epithelial cells like adenocarcinoma. GIST is defined by KIT (CD117) or PDGFRA gene mutations detectable by IHC staining and molecular testing. Three key differences from gastric adenocarcinoma: GIST does not spread to lymph nodes — no lymphadenectomy is required (wedge resection alone is adequate for localised GIST); GIST is exquisitely sensitive to imatinib (Gleevec) targeted therapy — transforming metastatic GIST from a rapidly fatal disease to a chronic manageable condition; and tumour rupture at surgery must be absolutely avoided — spilling GIST cells creates peritoneal sarcomatosis. KIT/PDGFRA molecular testing is mandatory before starting imatinib — PDGFRA D842V mutation is imatinib-resistant and requires avapritinib.

Gastric NETs (carcinoids) arise from enterochromaffin-like (ECL) cells of the gastric mucosa. Three types: Type 1 (most common, 70–80%) — multiple small polyps associated with autoimmune gastritis and high gastrin; usually benign behaviour, managed by endoscopic resection and surveillance. Type 2 (5–10%) — associated with Zollinger-Ellison syndrome and MEN1; moderately aggressive, treated by endoscopic resection and gastrinoma management. Type 3 (sporadic, 15–20%) — solitary tumours above 2cm, not associated with gastrin excess; most aggressive behaviour, requiring formal gastrectomy with lymphadenectomy. Well-differentiated gastric NETs are staged with Ga-68 DOTATATE PET-CT; poorly differentiated neuroendocrine carcinoma (NEC) is treated with platinum-etoposide chemotherapy. PRRT with Lu-177 DOTATATE is effective for progressive G1/G2 gastric NETs with adequate somatostatin receptor expression.

Peritoneal carcinomatosis — spread of gastric cancer to the peritoneal lining — is the most common pattern of Stage IV gastric cancer and carries the worst prognosis among gastric cancer metastatic sites. Detection: staging laparoscopy with peritoneal washing cytology is more sensitive than CT for early peritoneal disease. Treatment: systemic chemotherapy (FLOT, FOLFOX, FOLFIRI or FOLFOXIRI combinations) is the primary treatment; HIPEC for gastric peritoneal disease remains investigational — the GASTRIPEC trial showed no benefit; some Asian series report benefit in highly selected patients with low PCI and CC-0 resection. Prophylactic HIPEC at gastrectomy for positive peritoneal cytology without visible deposits is under investigation (GASTRICHIP trial). All patients with gastric peritoneal disease should be reviewed at a specialist MDT with experience in this area.

Total gastrectomy removes the entire stomach — profoundly affecting nutrition. Immediate post-operative: feeding via jejunostomy tube placed at surgery; gradual transition to oral fluids from day 3–5; soft diet by week 2. Long-term dietary adaptation: 6–8 small meals per day instead of 3 large meals — the gastric reservoir is gone; food moves rapidly into the small bowel. Dumping syndrome: early dumping (30 minutes after eating — sweating, dizziness, palpitations from rapid glucose surge) — prevented by avoiding sugar, eating slowly, not drinking with meals. Late dumping (2–3 hours after eating — hypoglycaemia) — prevented by small frequent meals, avoiding refined carbohydrates. Mandatory supplements after total gastrectomy for life: Vitamin B12 (monthly injection — intrinsic factor is lost); iron; calcium and Vitamin D; and multivitamins. Annual nutritional blood tests monitor for deficiencies. Dietitian review every 6 months is strongly recommended.

The Whipple procedure — pancreaticoduodenectomy — removes the pancreatic head, duodenum, distal bile duct, gallbladder, and often the distal stomach for pancreatic head cancer. Three anastomoses reconstruct the GI tract: pancreaticojejunostomy (pancreatic duct to bowel), hepaticojejunostomy (bile duct to bowel), and gastrojejunostomy (stomach to bowel). The operation takes 5–8 hours with hospital stay of 7–10 days at specialist centres. Five-year survival for pancreatic cancer after R0 Whipple is 20–25%; node-negative R0 disease achieves 35–40%. Periampullary cancers (ampullary, distal bile duct, duodenal) have significantly better post-Whipple survival of 40–60%. Adjuvant FOLFIRINOX or gemcitabine plus nab-paclitaxel for 6 months after surgery is the standard. Dr. Gore performs robotic Whipple at Sahyadri Manipal Hospital, Pune.

Hepatectomy — surgical removal of the cancer-bearing liver segments — is the only potentially curative treatment for colorectal liver metastases (CRLM), achieving 30–50% five-year survival. The liver is divided into eight Couinaud segments; major hepatectomy removes three or more segments. Critical safety requirement: adequate Future Liver Remnant (FLR) — minimum 20–25% for a healthy liver, 30–40% after chemotherapy-damaged liver. ICG fluorescence identifies segment boundaries for precise anatomical resection and detects occult liver metastases not visible on CT or MRI in 15–25% of CRLM operations. Portal Vein Embolisation (PVE) hypertrophies the FLR before major hepatectomy when it is borderline — performed radiologically 4–6 weeks before surgery. The liver regenerates fully within 4–6 weeks of major resection.

Yes — and this is the most important message in GI oncology for Stage IV patients. R0 hepatectomy for colorectal liver metastases achieves genuine long-term cure in 30–50% of carefully selected patients — with 10-year survivors well documented. This is achieved by no other treatment. The obstacle: fewer than 20% of CRLM patients are resectable at presentation. Solutions: chemotherapy conversion — FOLFOX or FOLFIRI plus bevacizumab or cetuximab shrinks 15–25% of initially unresectable CRLM to resectable; two-stage hepatectomy clears bilateral disease in two planned operations; PVE hypertrophies the future remnant enabling more extensive resection. Many patients told their liver metastases are inoperable are successfully resected at specialist HPB surgery centres. A second opinion from Dr. Gore — reviewing the actual CT images — is essential. Call 88558 10010.

Two-stage hepatectomy (TSH) enables curative resection of bilateral colorectal liver metastases — where resecting all deposits in a single operation would leave insufficient liver. Stage 1: remove metastases from the smaller-deposit lobe (usually left lobe) and ligate or embolise the portal vein to the right lobe (PVE) — inducing right lobe hypertrophy. After 4–8 weeks of chemotherapy and liver hypertrophy: Stage 2: right hemihepatectomy removing the right lobe with remaining metastases. TSH achieves five-year survival of 25–35% in carefully selected patients who could not otherwise be cured. Patient selection is critical: no extra-hepatic disease; adequate hepatic reserve; and biology suggesting responsiveness to chemotherapy. TSH is performed at specialist HPB centres by experienced hepatic surgeons. MDT review with a dedicated hepatic imaging team is essential before planning.

When colorectal cancer and liver metastases are diagnosed simultaneously, three management approaches are used depending on patient and tumour factors. Staged resection: colon/rectal cancer surgery first, liver resection 8–12 weeks later after recovery — the standard approach for symptomatic primary tumours (bleeding, obstruction). Simultaneous resection: colon and liver resection in the same operation — for selected patients with a small number of peripheral liver metastases amenable to minor hepatectomy and low-risk primary tumour resection; avoids a second operation but carries higher morbidity. Liver-first approach: liver resection first — for patients with high-risk liver metastases (approaching vascular structures, large volume) where early liver clearance improves overall prognosis; the primary tumour is resected after liver recovery. Perioperative systemic chemotherapy (FOLFOX) is given around the surgical procedures in all approaches.

RFA destroys liver tumours using heat delivered through a needle under image guidance — without surgical incision. Most effective for tumours under 3cm not adjacent to major blood vessels (heat sink effect reduces efficacy near large vessels). Local recurrence rate after RFA: 10–20% — significantly higher than after surgical resection (under 5%). RFA is used when surgical resection is not feasible — due to inadequate FLR, unfavourable tumour location (close to major vessels or bile ducts), or patient fitness precluding major surgery. MWA (Microwave Ablation) produces larger ablation zones and is less affected by the heat sink effect — increasingly preferred over RFA for liver metastases. ICG fluorescence after ablation confirms complete coverage of the tumour margin. When resection is feasible and safe, surgery remains oncologically superior to ablation for colorectal liver metastases.

HCC arises from hepatocytes — most commonly in a cirrhotic liver from Hepatitis B, Hepatitis C, alcoholic liver disease, or NAFLD. Staged by BCLC system combining tumour extent, liver function (Child-Pugh score), and performance status. Treatment by BCLC stage: BCLC-A (early) — surgical resection (curative for non-cirrhotic patients) or liver transplantation within Milan criteria (single nodule under 5cm or 3 nodules under 3cm, no vascular invasion) for cirrhotic patients; BCLC-B (intermediate) — TACE (Transarterial Chemoembolisation); BCLC-C (advanced) — atezolizumab plus bevacizumab (IMbrave150) or sorafenib systemically. AFP monitoring and 6-monthly liver ultrasound surveillance is essential for all cirrhotic patients — detecting HCC at an early, resectable stage. ICGR-15 (ICG retention at 15 minutes) quantifies functional hepatic reserve before resection in cirrhotic patients.

Cholangiocarcinoma is classified by location. Intrahepatic: hepatectomy with adequate margins (at least 1cm or the nearest liver segment boundary). Perihilar or Klatskin tumour (bifurcation): the most complex HPB operation — extended hepatectomy with en bloc bile duct excision, often requiring portal vein reconstruction; caudate lobe resection is mandatory. Distal bile duct cancer: Whipple procedure. Only 30–40% are resectable at diagnosis — jaundice without a clear biliary cause requires urgent investigation. R0 resection is the only curative treatment. Adjuvant capecitabine (BILCAP trial) is recommended after R0 resection. Unresectable disease: gemcitabine plus cisplatin plus durvalumab (first-line). FGFR2 inhibitors (pemigatinib) for FGFR2-rearranged intrahepatic cholangiocarcinoma — molecular testing is mandatory. Biliary stenting relieves jaundice.

TACE — Transarterial Chemoembolisation — delivers chemotherapy (doxorubicin) mixed with embolic particles directly into the hepatic artery branches supplying the tumour — cutting off blood supply while achieving high local drug concentrations. The technique exploits the dual blood supply of the liver: normal hepatocytes receive 75% of blood from the portal vein (which is not embolised), while liver tumours are almost exclusively supplied by the hepatic artery (which is targeted). TACE is the standard locoregional treatment for intermediate-stage HCC (BCLC-B) and is used for unresectable NET liver metastases. Drug-eluting bead TACE (DEB-TACE) releases chemotherapy slowly — improving drug delivery and reducing systemic side effects compared to conventional TACE. TACE can downstage HCC to within Milan criteria — bridging patients to liver transplantation while waiting on the transplant list.

Distal pancreatectomy removes the body and tail of the pancreas — with the spleen (splenectomy is standard for cancer as it removes lymph nodes at the splenic hilum and along the splenic artery). Unlike Whipple surgery, no reconstruction is needed — the pancreatic stump is stapled or sutured closed. The most feared complication is pancreatic fistula — leakage from the stump — occurring in 15–25% of cases but usually managed conservatively with drain, nil by mouth, and octreotide. RAMPS (Radical Antegrade Modular Pancreatosplenectomy) — dissecting from medial to lateral — addresses the retroperitoneal margin (between the posterior surface of the pancreas and the anterior surface of the left adrenal and Gerota's fascia) first, achieving higher R0 rates for body/tail pancreatic cancer. Robotic distal pancreatectomy achieves equivalent R0 and nodal clearance to open surgery with significantly less blood loss.

Pancreatic fistula (POPF — Post-Operative Pancreatic Fistula) is the most clinically significant complication of Whipple surgery — occurring in 15–25% of cases. It arises from anastomotic breakdown of the pancreaticojejunostomy — allowing pancreatic juice to leak into the abdominal cavity. The International Study Group on Pancreatic Fistula (ISGPF) classifies fistula as Grade A (biochemical leak, no clinical consequence), Grade B (requiring drain manipulation or medical management), and Grade C (requiring re-operation or life-threatening). Risk factors: soft pancreatic texture (less fibrotic pancreas holds sutures poorly), small pancreatic duct diameter, and high-fat pancreatic parenchyma. Management: most Grade B fistulas resolve with drain maintenance, nil by mouth, and octreotide; Grade C fistulas require re-operation. Robotic Whipple's precise anastomotic technique reduces high-grade fistula rates compared to open surgery.

Gallbladder cancer — often discovered incidentally after laparoscopic cholecystectomy for presumed benign stones — requires management determined by T-stage. T1a (limited to mucosa): simple cholecystectomy is adequate — curative in over 95%. T1b (into muscle layer): simple cholecystectomy may be adequate; extended resection debated. T2 (into perimuscular connective tissue): extended cholecystectomy with en bloc resection of liver segments IVb and V plus hepatoduodenal ligament lymphadenectomy is the standard — evidence shows significantly improved survival over simple cholecystectomy. T3/T4: extended hepatectomy and bile duct resection if involved. Laparoscopic cholecystectomy for unsuspected gallbladder cancer carries port-site metastasis risk — all laparoscopic cholecystectomy specimens must be sent for histology and urgent re-referral to a specialist HPB surgeon if cancer is found.

FLR is the volume of functional liver remaining after the planned hepatectomy — the most critical safety requirement before major liver surgery. CT volumetry precisely calculates each Couinaud segment volume. Minimum safe FLR thresholds: 20–25% for a normal healthy liver; 30–35% after prolonged preoperative chemotherapy (chemotherapy-associated liver injury — CALI); 40% or more for a cirrhotic liver. Portal Vein Embolisation (PVE): a radiological procedure occluding the portal vein branch to the liver being resected — stimulating compensatory hypertrophy of the planned remnant. PVE performed 4–6 weeks before surgery; CT volumetry at 4–6 weeks confirms adequate hypertrophy (typically 30–40% volume increase) before proceeding. Without adequate FLR, major hepatectomy risks post-hepatectomy liver failure — a life-threatening complication with very high mortality. FLR calculation is the most important safety step in planning any major liver resection.

Peritoneal carcinomatosis from colorectal cancer — cancer cells disseminating from the primary tumour to seed the peritoneal lining — occurs in 7–15% of colorectal cancer patients at some point in their disease course. It presents as abdominal distension, ascites, pain, and bowel obstruction. Staging uses the PCI (Peritoneal Cancer Index) developed by Sugarbaker — dividing the abdomen into 13 regions, each scored 0–3 by tumour deposit size (maximum PCI 39). PCI under 15–20 predicts meaningful benefit from HIPEC; PCI above 20–25 indicates extensive disease where CC-0 cytoreduction may not be achievable. CT imaging underestimates peritoneal disease — staging laparoscopy before planning HIPEC provides the most accurate PCI assessment. HIPEC is the only treatment achieving long-term survival in colorectal peritoneal metastases — 25–35% five-year survival after CC-0 CRS+HIPEC.

SIRT — also called Yttrium-90 (Y-90) radioembolisation — delivers radioactive microspheres directly into the hepatic artery, which lodge in tumour vasculature and irradiate liver tumours from within. Like TACE, it exploits hepatic artery delivery targeting liver tumours while sparing normal hepatocytes (supplied predominantly by portal vein). SIRT is used for: unresectable colorectal liver metastases where TACE is less effective due to hypovascular nature of CRC; unresectable primary liver tumours (HCC, intrahepatic cholangiocarcinoma); and as a bridge to transplantation. SIRFLOX trial showed SIRT plus FOLFOX increases liver-specific PFS in metastatic CRC. SIRT is not curative — it is a locoregional palliative treatment aiming to control liver disease, reduce tumour burden, and potentially convert unresectable to resectable in carefully selected patients.

Modern hepatic surgery does not apply a fixed numerical limit on the number of colorectal liver metastases that can be resected. The operative principle is that all deposits must be removed with R0 margins while leaving an adequate FLR — the number is irrelevant if both conditions are met. Historical criteria restricting resection to fewer than 4 metastases, no larger than 5cm, and no extrahepatic disease are now considered outdated — large observational and surgical series demonstrate equivalent survival in patients with more extensive CRLM when R0 resection and adequate FLR are achievable. Extrahepatic disease (lung, peritoneal, lymph node) is not an absolute contraindication — selected patients with limited extrahepatic disease combined with resectable liver disease achieve meaningful long-term survival. The operative decision must be made by an experienced HPB surgeon reviewing the full imaging — not by a radiologist's report.

Neoadjuvant (preoperative) chemotherapy for CRLM serves three purposes: shrinking initially unresectable metastases to resectable (conversion chemotherapy); treating systemic micrometastatic disease; and testing tumour biology — progression on chemotherapy predicts poor surgical outcomes. Regimens: FOLFOX or FOLFIRI plus bevacizumab (RAS-mutant tumours); FOLFOX or FOLFIRI plus cetuximab or panitumumab (RAS wild-type, left-sided primary — CRYSTAL, PRIME trials). Optimal chemotherapy duration before liver surgery: typically 3–4 months (6–8 cycles) — longer duration increases liver parenchymal injury (sinusoidal obstruction syndrome from oxaliplatin; steatohepatitis from irinotecan) compromising hepatic regeneration after resection. Bevacizumab should be discontinued 6–8 weeks before surgery — it impairs wound healing. Timing of liver surgery after chemotherapy is a critical oncological decision made at HPB MDT.

ICG (Indocyanine Green) fluorescence is integrated into robotic and open liver surgery using near-infrared cameras. Applications in liver cancer surgery: Occult metastasis detection — ICG administered IV 24–72 hours pre-operatively is selectively retained in liver metastases and primary liver tumours, which fluoresce intensely under near-infrared light; identifies additional deposits not visible on pre-operative CT or MRI or to the naked eye during surgery in 15–25% of CRLM operations. Anatomical segment mapping — ICG injected into the portal vein branch of the segment being resected demarcates the segment boundary by staining it green — enabling precise anatomical segmentectomy. Bile duct mapping — ICG identifies bile duct anatomy during hepatectomy, reducing inadvertent bile duct injury. Tumour margin confirmation — fluorescent boundary of the tumour aids R0 margin assessment.

Pancreatic cancer symptoms in the head: painless obstructive jaundice — yellowing of the skin and eyes with dark urine and pale stools — the most common and clinically detectable presentation; itching (pruritus); and weight loss. Pancreatic body/tail cancer: typically presents later — epigastric or back pain (from coeliac plexus invasion), weight loss, and new-onset diabetes (destruction of insulin-producing tissue). Non-specific symptoms early: fatigue, anorexia, and vague abdominal discomfort. Migratory thrombophlebitis (Trousseau's sign) — superficial thrombophlebitis in unusual locations. Any new-onset diabetes or sudden worsening of previously controlled diabetes in a patient above 50 should prompt CA 19-9 measurement and CT scan — pancreatic cancer can present as new-onset diabetes. Painless jaundice is a surgical emergency — requires urgent CT and hepatobiliary surgery review within days, not weeks.

Pancreatic cancer survival after Whipple surgery (R0 resection) remains the most honest discussion in oncology. Overall: five-year survival 20–25% after R0 resection with adjuvant chemotherapy. Favourable subgroups: node-negative (N0) R0 resection — five-year survival 35–45%; small tumours under 2cm — better outcomes. Unfavourable: positive nodes significantly worsen prognosis; R1 resection — five-year survival under 10%. Adjuvant chemotherapy (modified FOLFIRINOX, 6 months — PRODIGE 24 trial: 54 month median OS vs 35 months with gemcitabine) or gemcitabine plus nab-paclitaxel significantly improves survival after Whipple surgery. BRCA1/2-mutant pancreatic cancer: olaparib (PARP inhibitor) as maintenance after platinum-based chemotherapy improves progression-free survival. Despite challenging outcomes, R0 Whipple surgery remains the only treatment offering any chance of long-term survival or cure for pancreatic cancer.

HIPEC — Hyperthermic Intraperitoneal Chemotherapy — combines cytoreductive surgery (CRS) removing all peritoneal tumour deposits with heated chemotherapy (41–43°C) circulated in the closed abdomen for 30–90 minutes. For GI cancers: colorectal peritoneal metastases (the most common GI indication — PCI under 15–20, CC-0 resection, five-year survival 25–35%); appendiceal cancer and Pseudomyxoma Peritonei (the most favourable indication — five-year survival 80–90% after complete CRS+HIPEC); selected gastric cancer with very limited peritoneal involvement at specialist centres (investigational); and primary peritoneal mesothelioma. HIPEC is not appropriate for extensive systemic metastases (liver, lung) beyond the peritoneum. HIPEC is available at Sahyadri Manipal Hospital, Pune. Call 88558 10010.

PCI — Peritoneal Cancer Index developed by Paul Sugarbaker — quantifies peritoneal tumour burden by scoring 13 abdominal regions (0–3 by deposit size, maximum 39). A lower PCI predicts greater HIPEC benefit: PCI under 15–20 for colorectal peritoneal metastases; PCI under 15 for gastric peritoneal disease; higher PCI acceptable for appendiceal PMP with favourable biology. PCI is assessed preoperatively on CT and confirmed at staging laparoscopy — CT consistently underestimates peritoneal disease. A very high PCI where CC-0 (no residual tumour) is not achievable means HIPEC is unlikely to benefit — the 8–14 hour operation cannot be justified without achievable complete cytoreduction. Diagnostic laparoscopy before committing to full CRS is an essential step in correct HIPEC patient selection.

PMP is a rare condition where mucus-secreting tumour cells — almost always from a Low-grade Appendiceal Mucinous Neoplasm (LAMN) — progressively fill the peritoneal cavity with mucinous material. PMP has unique biology: slow growth; confinement to the peritoneum for years; and preserved general health despite large mucus volumes. CRS+HIPEC — complete peritonectomy procedures followed by HIPEC — achieves five-year survival of 80–90% for low-grade PMP after complete cytoreduction. Without specialist treatment, PMP is eventually fatal from bowel obstruction. Diagnosis is often incidental at appendicectomy — the pathology report must be carefully reviewed. Any patient diagnosed with a mucinous appendiceal tumour (LAMN or low-grade mucinous adenocarcinoma) must be referred urgently to a CRS/HIPEC specialist centre for MDT review.

CRS removes all visible peritoneal tumour deposits — stripping peritoneum from abdominal surfaces, diaphragm, pelvic floor, and mesentery; resecting involved bowel, spleen, or other organs if required. The goal is CC-0: no visible residual tumour. The completeness of cytoreduction score: CC-0 (no residual) — essential for curative HIPEC benefit; CC-1 (residual under 2.5mm — within HIPEC penetration depth); CC-2 (2.5mm–2.5cm); CC-3 (above 2.5cm). Survival benefit from HIPEC is realised only after CC-0 (and possibly CC-1) resection — CC-2 and CC-3 residual disease is not effectively treated by HIPEC drug penetration. The CC score is assessed intraoperatively by the surgeon after completing CRS — the decision to proceed with HIPEC (when CC-0 is confirmed) is made at that point.

CRS+HIPEC is one of the most demanding major operations in GI surgery reflecting the 8–14 hour operative duration and the extent of visceral resections required for peritoneal clearance. ICU phase (1–2 days): cardiovascular monitoring, fluid balance, kidney function assessment (critical with cisplatin-based HIPEC), and drain output review. High dependency phase (2–5 days): progressive mobilisation, drain removal when output is non-bilious and low, transition to oral fluids. Ward phase (5–10 days): soft then normal diet progression, supervised physiotherapy, wound care. Hospital discharge at 10–14 days. Home recovery: 6–8 weeks before desk work; 10–12 weeks for physical roles. Fatigue dominates for 4–8 weeks. Pre-operative nutritional optimisation is essential — malnutrition is common in peritoneal disease patients and significantly increases post-HIPEC complication risk.

Chemotherapy choice for colorectal peritoneal metastases HIPEC: oxaliplatin — the most widely used agent for CRC; administered at 460 mg/m² in a 5% dextrose carrier for 30 minutes at 42–43°C; concurrent IV 5-FU and leucovorin potentiates the intraperitoneal oxaliplatin effect. Mitomycin C — used in the original French Elias protocol; administered at 35 mg/m² in normal saline for 90 minutes at 41–42°C. Both achieve equivalent oncological outcomes for CRLM in published series — oxaliplatin has largely replaced MMC in European practice due to faster administration and favourable side effect profile. Peritoneal oxaliplatin exposure is 25 times higher than plasma concentration — the core pharmacological rationale for intraperitoneal drug delivery for peritoneal disease. Renal function does not need specific monitoring for oxaliplatin-based HIPEC (unlike cisplatin).

Appendiceal cancers range in biological behaviour. Carcinoid (NET) under 2cm: appendicectomy alone — curative in over 95%; the appendix specimen must always be sent for histology even after laparoscopic appendicectomy. Carcinoid above 2cm or at the base: right hemicolectomy. Goblet cell carcinoid (GCC): aggressive behaviour — right hemicolectomy plus staging for peritoneal and systemic disease. LAMN (Low-grade Appendiceal Mucinous Neoplasm): appendicectomy for intact LAMN; if ruptured, urgent referral to CRS/HIPEC centre — mucin-seeding produces PMP. Mucinous adenocarcinoma: right hemicolectomy plus staging laparoscopy; any peritoneal involvement requires CRS+HIPEC evaluation. The pathological report of every appendicectomy specimen must be reviewed for unexpected mucinous neoplasm — a finding that completely changes subsequent management.

Watch and Wait refers to deferring or potentially avoiding TME surgery for rectal cancer patients who achieve complete clinical response (cCR) to neoadjuvant chemoradiation — confirmed by all three assessment modalities: digital rectal examination (no palpable tumour); pelvic MRI (mrTRG 1 or 2, fibrotic scar replacing tumour); and flexible sigmoidoscopy (mucosal whitening/telangiectasia at former tumour site, no residual mucosal disease). Surveillance: clinical examination and MRI every 3 months for 2 years; 6-monthly thereafter. Local regrowth in 15–25% of cCR patients — most salvaged by surgery at time of regrowth. Watch and Wait avoids major pelvic surgery (TME), its complications, and the temporary or permanent stoma. It requires specialist centre assessment, confirmed complete response (partial response does not qualify), and strict surveillance commitment by both patient and clinical team.

Appendiceal PMP represents the most favourable indication for CRS+HIPEC — with the best long-term outcomes of any peritoneal malignancy treated with this approach. Five-year survival after complete CRS+HIPEC for low-grade PMP: 80–90% at specialist centres. Ten-year survivors are well documented. High-grade appendiceal mucinous adenocarcinoma has a less favourable but still meaningful prognosis — five-year survival 40–60% after complete CRS+HIPEC. The extent of CRS required for PMP often involves total peritonectomy of all six peritoneal regions plus bilateral oophorectomy (ovaries are almost always involved in PMP), splenectomy, and rectosigmoid resection. The completeness of cytoreduction is the most critical prognostic factor — CC-0 doubles survival compared to any residual disease. Referral to Dr. Gore's HIPEC programme at Sahyadri Manipal Hospital: call 88558 10010.

HIPEC suitability requires three-domain assessment. Oncological: peritoneal disease from an appropriate primary (colorectal, appendiceal); no systemic metastases beyond the peritoneum; PCI within the beneficial range (under 15–20 for colorectal); stable or responding biology on chemotherapy. Technical: CC-0 cytoreduction achievable — confirmed on preoperative CT and staging laparoscopy before committing to full CRS. Patient fitness: ECOG performance status 0–1; adequate kidney function for cisplatin-based HIPEC; nutritional status allowing recovery from major surgery; absence of prohibitive medical comorbidities. Call 88558 10010 or WhatsApp 84118 08284 to book a HIPEC suitability consultation at Silver Leaf Clinic, Hadapsar, Pune. Bring full CT staging, histopathology, and prior chemotherapy details to the first appointment.

Primary peritoneal mesothelioma is a rare malignancy arising from the peritoneal mesothelial lining — distinct from pleural mesothelioma and not necessarily related to asbestos exposure. The peritoneal variant is more amenable to surgical treatment than pleural mesothelioma — CRS+HIPEC achieves five-year survival of 40–60% in carefully selected patients. HIPEC for peritoneal mesothelioma uses cisplatin plus doxorubicin — 60 minutes at 41°C. Patient selection: epithelioid histology (best prognosis); absence of systemic disease; PCI achievable to CC-0; and adequate performance status and organ reserve. Systemic chemotherapy (pemetrexed plus cisplatin) provides palliation for unresectable disease. Immunotherapy (nivolumab plus ipilimumab) has emerging evidence for mesothelioma — discussed at specialist MDT for each patient. Referral to a specialist CRS/HIPEC centre is essential for all peritoneal mesothelioma patients.

HIPEC (Hyperthermic Intraperitoneal Chemotherapy) and PIPAC (Pressurised Intraperitoneal Aerosol Chemotherapy) are both intraperitoneal treatments with fundamentally different intent and patient selection. HIPEC: potentially curative; combined with maximal CRS to CC-0; large-volume heated liquid chemotherapy for 30–90 minutes; single 8–14 hour major operation. PIPAC: palliative; delivers aerosolised chemotherapy laparoscopically under pressure (12 mmHg) without cytoreduction; suitable for extensive peritoneal disease not amenable to CC-0, or patients too frail for CRS+HIPEC; repeated every 6–8 weeks. HIPEC has level-1 evidence (randomised trials); PIPAC remains investigational. PIPAC allows tissue biopsy at each session — monitoring response and biological evolution of peritoneal disease. Both are available at specialist peritoneal cancer centres.

The Sugarbaker technique defines six systematic peritonectomy procedures addressing all parietal peritoneal surfaces: greater omentectomy and splenectomy (left upper abdomen); left upper quadrant peritonectomy stripping the left diaphragm and left paracolic gutter peritoneum; right upper quadrant peritonectomy stripping the right diaphragm and liver capsule (Glisson's capsule) if involved; lesser omentectomy; pelvic peritonectomy with rectosigmoid resection (sigmoid and upper rectum removed with en bloc pelvic peritoneum); and right colectomy when the caecum or right colon is involved. Visceral resections (bowel, ovaries, gallbladder, uterus, ureter, spleen) are added based on disease distribution. These procedures form the foundation of CRS+HIPEC at Sahyadri Manipal Hospital, Pune — combining Paul Sugarbaker's systematic principles with robotic surgical precision.

Pre-HIPEC nutritional optimisation is as important as surgical technique for reducing post-operative complication rates. Peritoneal disease patients commonly have significant malnutrition — from ascites (causing early satiety), malabsorption, and reduced oral intake. Preparation protocol: immunonutrition supplements containing arginine, omega-3 fatty acids, and nucleotides for 5–7 days pre-operatively — proven to reduce infection rates and improve immune function; high-protein oral supplementation to correct hypoalbuminaemia (target serum albumin above 35 g/L before surgery); carbohydrate loading the night before and morning of surgery to reduce post-operative insulin resistance. Patients with albumin below 30 g/L: 7–14 days of parenteral or nasojejunal enteral nutrition before surgery is mandatory. A dedicated clinical dietitian experienced in peritoneal disease management works with Dr. Gore's team at Sahyadri Manipal Hospital to assess every HIPEC patient.

Repeat CRS+HIPEC is performed at specialist centres for selected patients with recurrent peritoneal disease after previous HIPEC. Requirements: full recovery from the first HIPEC (typically 12 or more months); recurrence limited to the peritoneum with no systemic spread; second-operation CC-0 technically achievable — more complex given adhesions from prior peritonectomy; adequate organ reserve; and favourable tumour biology (not rapidly progressive through systemic chemotherapy). Surgical complexity is significantly greater at re-operation due to adhesions from prior peritonectomy — increasing bowel injury risk and operative duration. Published data from experienced HIPEC centres show meaningful survival benefit in carefully selected repeat HIPEC patients — five-year survival of 20–30% in the best series. All repeat HIPEC decisions require comprehensive MDT review at a centre with specific expertise in redo peritoneal surgery. Call 88558 10010.

Anal canal squamous cell carcinoma is primarily treated with chemoradiation — not surgery — the Nigro protocol (5-FU plus Mitomycin C plus 50–60 Gy external beam radiotherapy) achieves complete clinical response in 60–80% of patients, preserving the anus and sphincter function without any surgery. Surgery (APR — abdominoperineal resection) is reserved only for: residual disease confirmed at 26-week post-chemoradiation assessment; or histologically confirmed local recurrence. Anal canal SCC is caused by HPV-16 and HPV-18 in over 85% of cases — it is a vaccine-preventable cancer. Any persistent perianal symptoms — bleeding, lump, pain, itching — lasting more than 3 weeks must be examined and biopsied; anal cancer is frequently and dangerously misdiagnosed as haemorrhoids, causing catastrophic treatment delays.

Anal canal cancer and rectal cancer arise in adjacent anatomical locations but differ fundamentally in cell type, biology, treatment, and prognosis. Anal canal cancer: almost always squamous cell carcinoma (SCC); caused by HPV in 85%; primarily treated with chemoradiation — surgery is the salvage for failures; chemoradiation achieves organ preservation in 60–80%; excellent prognosis with early detection. Rectal cancer: almost always adenocarcinoma; not HPV-related; primarily treated with surgery (TME) — chemoradiation is neoadjuvant (given to shrink the tumour before surgery, not as primary treatment); sphincter preservation is the surgical goal; LARS is a major quality-of-life consideration. A cancer at the anorectal junction requires expert histological and endoscopic assessment to correctly classify as rectal adenocarcinoma or anal SCC — the treatment pathway is completely different.

GIST — Gastrointestinal Stromal Tumour — is a mesenchymal tumour arising from interstitial cells of Cajal in the GI wall. Most common sites: stomach (60%), small bowel (25%), colorectum (5%), and oesophagus (rare). Defined by KIT (CD117, 85%) or PDGFRA (10%) mutations — confirmed by IHC staining and molecular testing. Three unique oncological principles: no lymphadenectomy required (GISTs spread haematogenously — lymph nodes are uninvolved); tumour capsule must never be ruptured at surgery — rupture seeds malignant cells causing peritoneal sarcomatosis; and imatinib (Gleevec) targeted therapy achieves response in over 80% of KIT exon 11 mutations, transforming metastatic GIST from a rapidly fatal disease to a chronic condition. Large rectal GISTs: neoadjuvant imatinib for 6–12 months shrinks the tumour, enabling sphincter-preserving resection and avoiding APR.

Appendiceal carcinoids (neuroendocrine tumours) are the most common appendiceal tumour — discovered in 0.3–0.5% of appendicectomy specimens. Most are small (under 1cm), incidental findings, benign in behaviour, and cured by simple appendicectomy alone. Management by size: under 2cm — appendicectomy is curative (metastatic risk under 2%); 2–3cm — borderline; right hemicolectomy recommended by most guidelines; above 2cm or at the appendiceal base — right hemicolectomy with mesenteric lymphadenectomy. G1/G2 carcinoids: good prognosis; staged with Ga-68 DOTATATE PET-CT; managed with SSA (octreotide LAR) and surgery. G3 poorly differentiated carcinoma: aggressive behaviour; platinum-etoposide chemotherapy. All appendicectomy specimens must be submitted for routine histopathology — carcinoid is frequently not suspected clinically and only identified on microscopy.

Colorectal NETs arise from enterochromaffin cells in the colonic or rectal mucosa. Rectal NETs are the most common site in the colorectum — typically presenting as small, submucosal polyps found incidentally at colonoscopy. Management by size: under 1cm — endoscopic resection (EMR or ESD) is curative; 1–2cm — endoscopic or transanal excision, depending on depth of invasion on EUS; above 2cm — formal anterior resection with lymphadenectomy (metastatic risk is high). Colonic NETs are less common — managed similarly to small bowel NETs by segmental resection with mesenteric lymphadenectomy. Well-differentiated colorectal NETs have good prognosis and respond to somatostatin analogues (octreotide LAR). Ki-67 index is the most critical prognostic marker — G1 (under 3%), G2 (3–20%), and G3 (above 20%) each have distinct biology, management, and prognosis.

Both ulcerative colitis (UC) and Crohn's disease (CD) significantly increase colorectal cancer risk. UC risk: 2% after 10 years, 8% after 20 years, 18% after 30 years of disease — risk highest in extensive pancolitis. Surveillance colonoscopy: annually or every 2 years from year 8–10 of pancolitis using chromoendoscopy with targeted biopsies. Cancer in UC is frequently flat (not polypoid) — chromoendoscopy (spraying dye onto the mucosa) improves flat lesion detection. Management of UC-associated cancer: restorative proctocolectomy (ileal pouch-anal anastomosis — IPAA) removes the entire at-risk colorectum while preserving faecal continence through a neo-rectal pouch. Crohn's-associated cancer: risk concentrated in chronically inflamed segments and stricture sites; surgical management individualized by location and extent of Crohn's disease.

A colorectal polyp is a growth projecting from the mucosal surface of the colon or rectum — the vast majority are benign but some subtypes have significant cancer potential. Types: hyperplastic polyps — no cancer risk; tubular adenoma — 1–5% cancer risk depending on size; tubulovillous adenoma — 10–20% cancer risk; villous adenoma — 30–40% cancer risk if above 4cm; sessile serrated lesion (SSL) — under-recognised cancer risk particularly in right colon; and traditional serrated adenoma (TSA). All adenomas and SSLs should be removed at colonoscopy — the adenoma-carcinoma sequence takes 10–15 years for most adenomas. Post-polypectomy surveillance colonoscopy timing depends on: number of polyps, size, histology (villous component, high-grade dysplasia), and completeness of removal — personalised by the gastroenterologist based on polyp findings.

Colorectal cancer can present with perforation — either directly through the tumour wall (tumour perforation) or from proximal colon caecal perforation due to obstruction. Perforation is a surgical emergency associated with peritonitis, haemodynamic instability, and systemic sepsis — requiring urgent resuscitation and emergency operation. Management of tumour perforation: emergency Hartmann's procedure in most cases — sigmoid resection with end colostomy, faecal peritoneal lavage; primary anastomosis avoided in contaminated field. Oncological implication: perforation dramatically worsens prognosis — free tumour cell spilling into the peritoneum upstages the patient and dramatically increases peritoneal recurrence risk. Perforation is an indication for consideration of adjuvant chemotherapy even in Stage II disease. HIPEC at a second operation — after recovery from emergency surgery — may be considered at specialist centres to reduce peritoneal recurrence risk.

Carcinoid syndrome — episodic flushing, explosive watery diarrhoea, bronchospasm, and right-sided cardiac valvular disease — occurs when serotonin and other vasoactive amines secreted by neuroendocrine tumours escape hepatic metabolism and reach the systemic circulation directly. This only occurs with liver metastases (portal blood from midgut NETs is inactivated by the liver — liver metastases bypass this). The most common GI NETs causing carcinoid syndrome: midgut NETs (ileal carcinoids) with liver metastases. Treatment: octreotide LAR (Sandostatin LAR 30mg monthly) controls symptoms in 70% of patients and has anti-proliferative effects; telotristat ethanolamine for refractory diarrhoea. Cardiac monitoring (echocardiography) annually — carcinoid heart disease (tricuspid regurgitation, pulmonary stenosis) occurs in 20–30% of patients with sustained carcinoid syndrome.

Peritoneal carcinomatosis — spread of cancer to the peritoneal lining — was historically considered an end-stage, uniformly terminal diagnosis treated only with palliative systemic chemotherapy. This view is now outdated. For selected patients with colorectal peritoneal metastases: CRS+HIPEC achieves five-year survival of 25–35% — genuinely curative outcomes in a significant proportion. For appendiceal PMP: CRS+HIPEC achieves five-year survival of 80–90% — one of the best cancer surgery outcomes of any malignancy. For ovarian cancer: HIPEC at interval debulking surgery improves survival by 12 months (OVHIPEC trial). The critical determinants of outcome are PCI score, completeness of cytoreduction (CC-0), tumour biology, and centre expertise. A specialist peritoneal surface oncology centre review is essential before accepting peritoneal carcinomatosis as untreatable. Call 88558 10010 for a HIPEC consultation.

Robotic surgery is the preferred approach for rectal cancer because the bony pelvis creates a narrow, confined operative space where open and standard laparoscopic instruments struggle to manoeuvre safely. The da Vinci Xi provides: 10x magnified 3D view of the mesorectal planes — enabling sharp, precise dissection within the correct fascial layer; 7-degree wristed instruments that flex and rotate inside the pelvis independently of the port site — overcoming the fulcrum limitation of straight laparoscopic instruments; tremor filtration ensuring millimetre-accurate dissection near the autonomic nerves and sphincter; and ICG fluorescence for perfusion assessment of the anastomosis before completion. Robotic rectal surgery consistently achieves lower CRM positivity rates, better nerve preservation for bladder and sexual function, and sphincter preservation in more patients than open or laparoscopic surgery.

Robotic colectomy uses the da Vinci Xi system for colon cancer resection — providing 3D magnification, 7-degree wristed instruments, and tremor filtration versus the 2D image and straight instruments of standard laparoscopy. The technical advantage of robotics for colectomy: higher-quality Complete Mesocolic Excision (CME) — the precise fascial plane dissection is facilitated by 3D vision and instrument wristing; intracorporeal anastomosis — the bowel join is performed inside the abdomen using robotic staplers — reducing the extraction wound size and incisional hernia risk compared to extracorporeal anastomosis through a separate incision. The da Vinci Xi's multi-arm design allows seamless transition from right hemicolectomy to sigmoid resection in the same operation without repositioning — useful for synchronous colon cancers or combined colon and liver resections.

Robotic ISR is the technique of choice for very low rectal cancers — tumours within 1–3cm of the dentate line — that would otherwise require APR and permanent colostomy. The internal anal sphincter (the involuntary smooth muscle layer of the sphincter complex) is dissected free of the external sphincter under 10x 3D robotic vision — separating the planes within the narrow intersphincteric groove with precision not achievable open or laparoscopically. The external sphincter (voluntary muscle controlling continence) is preserved, allowing coloanal anastomosis at the dentate line. ISR is technically demanding — requiring meticulous patient selection: the external sphincter must be radiologically and clinically uninvolved; pre-operative sphincter function must be adequate; and the patient must be counselled honestly about the expected severe LARS in the first 12–24 months after ISR.

Robotic D2 gastrectomy removes the stomach for gastric cancer — with a comprehensive D2 lymph node dissection removing the second tier of perigastric and coeliac axis nodes. The suprapancreatic nodal dissection — nodes along the hepatic artery, left gastric artery, splenic artery, coeliac trunk, and portal vein — is the most technically demanding and oncologically critical step of D2 gastrectomy. The robotic 10x 3D view facilitates this dissection significantly — reducing the risk of inadvertent pancreatic or splenic vessel injury while ensuring complete nodal clearance. Robotic D2 gastrectomy achieves equivalent nodal yield and R0 rates to open gastrectomy with significantly less blood loss (200 vs 400ml), shorter hospital stay (5–7 vs 8–12 days), and faster recovery. FLOT neoadjuvant chemotherapy is given before surgery for Stage II–III gastric cancer.

Robotic pancreaticoduodenectomy (Whipple) removes the pancreatic head, duodenum, bile duct, and gallbladder through 5–6 small port incisions. The oncologically critical step — dissection of the superior mesenteric artery and vein, the uncinate process, and the retroperitoneal margin — is facilitated by the 10x 3D view and wristed instruments, enabling precise vascular dissection without the limitations of straight open instruments. The three anastomoses (pancreaticojejunostomy, hepaticojejunostomy, gastrojejunostomy) are constructed robotically with intracorporeal suturing — particularly the pancreaticojejunostomy, where precise, tension-free anastomosis reduces high-grade pancreatic fistula risk. Robotic Whipple achieves equivalent R0 resection and nodal yield to open surgery with significantly less blood loss (300 vs 800ml) and shorter hospital stay (7 vs 12 days).

ICG (Indocyanine Green) fluorescence is integrated into the da Vinci Xi robotic platform through the FireFly near-infrared camera — providing real-time fluorescence imaging without changing instruments during robotic GI surgery. Dr. Gore uses ICG routinely for: anastomotic perfusion — confirming blood supply to the bowel join before completion (PILLAR III trial: reduces clinical anastomotic leak from 12% to 1.4%); occult liver metastasis detection — ICG administered 24–72 hours pre-operatively is retained in liver metastases and fluoresces under NIR light, identifying additional deposits in 15–25% of CRLM operations; liver segment mapping — portal vein injection identifies segment boundaries for precise anatomical resection; bile duct mapping — identifies biliary anatomy during hepatectomy; and gastric conduit perfusion — confirms blood supply to the conduit tip during RAMIE esophagectomy before anastomosis.

ROLARR — Robotic vs LAparoscopic Resection for Rectal cancer — is the largest randomised controlled trial comparing robotic and laparoscopic rectal cancer surgery (JAMA 2017; 471 patients; 29 international centres). Results: equivalent oncological outcomes — R0 resection rates, CRM positivity, lymph node yield, and completeness of TME; significantly lower conversion rate to open surgery for robotic (8.1% vs 12.2%) — particularly in male patients with a narrow pelvis. The REAL trial subsequently confirmed robotic TME achieves significantly better preservation of urinary and sexual function (autonomic nerve preservation) compared to laparoscopic TME. Long-term data from high-volume robotic rectal cancer centres consistently show local recurrence rates under 5% — the benchmark of quality TME surgery.

While CRS (cytoreductive surgery) is currently performed as an open operation in most HIPEC programmes due to the extensive multi-quadrant peritoneal stripping required, robotic assistance has a growing role in: diagnostic staging laparoscopy before committing to full CRS — determining PCI score and CC-0 feasibility laparoscopically; PIPAC (Pressurised Intraperitoneal Aerosol Chemotherapy) — a laparoscopic/robotic procedure delivering pressurised chemotherapy for palliative peritoneal disease; and selected limited peritoneal disease where robotic resection of peritoneal deposits enables a minimally invasive approach. The full Sugarbaker CRS procedure for extensive peritoneal disease remains an open operation due to the requirement for systematic multi-quadrant peritonectomy requiring unrestricted access. Robotic technology continues to evolve — limited peritoneal disease may increasingly be addressed robotically in the future.

RAMIE — Robotic Assisted Minimally Invasive Esophagectomy — is a two-phase operation: Phase 1, thoracoscopic phase — robotic dissection of the oesophagus from the mediastinum with mediastinal lymphadenectomy, performed with the patient in left lateral decubitus; Phase 2, abdominal phase — robotic mobilisation of the stomach, creation of the gastric conduit (fashioning the stomach into a tube), and preparation for anastomosis with the patient supine. ICG fluorescence confirms blood supply to the gastric conduit tip before anastomosis — preventing conduit tip ischaemia, the most feared post-operative complication causing anastomotic necrosis. RAMIE achieves lower pulmonary complication rates (pneumonia, atelectasis) and shorter ICU stay than conventional open Ivor Lewis esophagectomy — an important advance for a procedure with historically high morbidity.

Robotic hepatectomy — removal of liver segments for primary liver cancer or colorectal liver metastases — uses the da Vinci Xi to provide 3D magnification during hepatic parenchymal transection and ICG fluorescence for precise segment identification and occult metastasis detection. Minor robotic hepatectomy (1–2 segments) is increasingly standard at specialist HPB centres for peripheral tumours. Major robotic hepatectomy (right or left hemihepatectomy) is performed at the most experienced centres. Advantages over open: less blood loss (the most critical intraoperative variable in liver surgery); lower wound complication rate; faster recovery. Equivalent oncological outcomes (R0 resection rates and disease-free survival) to open hepatectomy are confirmed in multiple published series. Robotic hepatectomy with ICG fluorescence represents the most advanced approach to liver cancer surgery currently available.

Robotic colorectal surgery follows ERAS (Enhanced Recovery After Surgery) protocols at Sahyadri Manipal Hospital Pune. Day of surgery: mobilisation — sitting out of bed within 4 hours of returning from theatre; drinking water; IV drip removed when oral intake is established. Day 1: walking in the ward; light diet (tea, biscuits, soup); physiotherapy for breathing and leg exercises. Day 2–3: progressing to normal diet; drain removed if output is serous and low. Hospital discharge: day 3–5 for right or sigmoid colectomy; day 4–7 for anterior resection. Home: light activities from week 1; avoid lifting above 5kg for 4 weeks; driving at 2–3 weeks; office work at 2–3 weeks; physical work at 4–6 weeks. After stoma reversal: bowel function settles over 3–6 months. First oncology review at 2–4 weeks; adjuvant chemotherapy referral at 4–6 weeks if Stage III.

Sahyadri Manipal Hospital, Hadapsar, Pune is the designated Robotic Cancer Surgery Centre of Excellence (ARIS accredited) for GI cancer in Pune — operating the da Vinci Xi platform under the leadership of Dr. Vinod T. Gore (FARIS Edinburgh, 300+ robotic procedures across all GI cancer types). The programme covers the full spectrum of robotic GI surgery: colorectal (TME, LAR, APR, ISR, colectomy, LARS management); HPB (Whipple, hepatectomy, distal pancreatectomy, CRLM); and upper GI (gastrectomy D2, RAMIE esophagectomy). ICG fluorescence is used as standard in all major robotic GI operations. OPD consultations at Silver Leaf Clinic, Hadapsar. Call 88558 10010 or WhatsApp 84118 08284. Full robotic programme details at bestroboticsurgeonpune.in.

Stoma reversal — closure of the defunctioning loop ileostomy — is most commonly performed laparoscopically (not requiring robotic assistance as it is a relatively brief, technically straightforward operation). The technique: the stoma loop is freed from the abdominal wall through a small incision at the stoma site; the two bowel limbs are mobilised and joined by stapled or hand-sewn anastomosis; bowel is returned to the abdomen and the wound is closed in layers. Hospital stay 3–5 days. Laparoscopic stoma reversal offers faster recovery than open reversal — the advantage is small as the incision is already limited to the stoma site. In selected patients where significant intra-abdominal adhesions are anticipated (prior peritonitis, multiple prior abdominal operations), laparoscopic adhesiolysis may be added — occasionally converting to open when access is restricted by dense adhesions.

Yes — and this is one of the most clinically significant advantages of robotic surgery for rectal cancer patients. The 10x 3D magnification in the narrow pelvis enables sphincter-preserving resection (LAR or ISR) in many patients who would require APR (permanent stoma) with open or laparoscopic surgery. Critical factors: neoadjuvant chemoradiation before surgery is essential for low rectal cancers — it shrinks the tumour and creates distance between the tumour and sphincter; robotic dissection in the intersphincteric plane preserves the external sphincter even when the tumour is within 1cm of the dentate line (ISR); and the surgeon's volume and robotic experience in ISR directly determines the proportion of patients avoiding permanent stoma. Before accepting an APR recommendation: always seek a second opinion at a specialist robotic rectal cancer centre. Call 88558 10010.

Anastomotic leak — breakdown of the bowel join after colorectal surgery — is the most feared and clinically significant post-operative complication, occurring in 3–5% of colonic and 5–10% of low rectal anastomoses. Inadequate blood supply to one end of the anastomosis is a major preventable cause. ICG fluorescence identifies ischaemic bowel segments before completing the anastomosis — the bowel is divided at the last point of adequate perfusion rather than at the planned level if that level is poorly perfused. The PILLAR III randomised trial confirmed intraoperative ICG assessment changes the planned anastomotic level in 7.9% of patients — reducing clinical anastomotic leak rate from 12% to 1.4% in the modified group. ICG perfusion assessment is now a standard component of all robotic colorectal anastomoses in Dr. Gore's programme at Sahyadri Manipal Hospital Pune.

Colonoscopy is the gold standard investigation for colorectal cancer diagnosis and prevention — a flexible camera (colonoscope) is passed via the anus under conscious sedation or general anaesthesia to visualise the entire colon and terminal ileum. During colonoscopy: biopsies are taken from any suspicious lesion; polyps are removed by snare polypectomy or EMR/ESD; tumour location is documented and tattooed with ink for surgical planning; and synchronous tumours or polyps are identified and biopsied. Bowel preparation the day before is essential for adequate visualisation. A colonoscopy takes 20–45 minutes — performed as a day procedure with discharge after 1–2 hours of recovery from sedation. Any adult with rectal bleeding, change in bowel habit, unexplained anaemia, or family history of CRC should have colonoscopy evaluated — not just a sigmoidoscopy or barium enema.

Flexible sigmoidoscopy examines only the last 60cm of the large bowel — the rectum and sigmoid colon. Colonoscopy examines the entire large bowel (150–180cm). For cancer diagnosis: colonoscopy is always required — flexible sigmoidoscopy alone is inadequate because 30–40% of colorectal cancers are in the right colon, beyond the reach of the sigmoidoscope. Flexible sigmoidoscopy is used for: quick assessment of rectal bleeding (examining the rectum and sigmoid); surveillance of the retained rectum after subtotal colectomy; and post-anterior resection surveillance of the anastomosis. Sigmoidoscopy is NOT an acceptable substitute for colonoscopy in colorectal cancer screening or investigation of symptomatic patients. Any patient with suspicious rectal symptoms evaluated by sigmoidoscopy alone requires full colonoscopy to exclude right-sided cancer or synchronous lesions.

CT colonoscopy (CTC) — also called virtual colonoscopy — uses CT imaging after gaseous distension of the colon to create 3D images of the colonic wall, detecting polyps and cancers. Advantages: non-invasive — no scope is passed; completed in 10–15 minutes; does not require sedation; can visualise the colon proximal to an obstructing rectal cancer when standard colonoscopy is incomplete. Limitations: cannot biopsy or remove lesions — any positive finding requires follow-up colonoscopy; radiation exposure from CT; less sensitive for flat lesions and polyps under 6mm; requires the same bowel preparation as conventional colonoscopy. CTC is used as a complementary investigation — not a replacement for colonoscopy — particularly when: colonoscopy is incomplete due to obstruction or patient intolerance; the patient has significant comorbidities making colonoscopy under sedation high-risk; and in centres without adequate colonoscopy capacity.

High-resolution pelvic MRI is the most important staging investigation for rectal cancer — providing critical information that CT cannot. MRI accurately assesses: T-stage (depth of tumour invasion in 5 bowel wall layers); circumferential resection margin (CRM) status — predicting local recurrence risk; extramural vascular invasion (EMVI) — predicting systemic recurrence; mesorectal fascia involvement; lymph node morphological assessment; relationship to the sphincter complex — determining sphincter preservation feasibility; and tumour height from the anal verge — guiding surgical approach. A high-quality MRI report from a radiologist experienced in rectal cancer staging directly influences: the decision on neoadjuvant chemoradiation; the exact surgical approach (LAR vs ISR vs APR); and whether Watch and Wait is appropriate after complete response. 3 Tesla MRI provides the highest spatial resolution for rectal cancer staging.

EUS provides the most accurate T-staging (depth of cancer invasion into the bowel wall) for oesophageal, gastric, and GEJ cancers — distinguishing T1 (mucosal/submucosal) from T2 (muscularis propria) invasion, which determines whether endoscopic resection (T1a) or surgery (T2+) is appropriate. EUS visualises the five distinct layers of the oesophageal or gastric wall — standard CT cannot differentiate wall layers. EUS-FNA (fine needle aspiration) samples suspicious lymph nodes in real time under ultrasound guidance — providing tissue confirmation of nodal metastasis before treatment planning. EUS is most valuable for: early oesophageal and gastric cancers where precise T-staging changes management; staging the coeliac axis nodes in gastric cancer; and assessing pancreatic tumour relationship to the portal vein and superior mesenteric artery (portal vein involvement determines resectability).

PET-CT combines metabolic imaging (FDG-PET detecting cancer's high glucose uptake) with anatomical localisation (CT). Indications in colorectal and GI cancer: evaluating equivocal liver or lung lesions on standard CT before major resection (confirms or excludes malignancy before committing to major surgery); pre-operative staging for oesophageal cancer (PET-CT changes staging in 20–30% of cases and is superior to CT for detecting distant metastases); planning HIPEC — confirming absence of systemic disease beyond the peritoneum; rectal cancer — detecting synchronous distant metastases not seen on CT before major pelvic surgery; and detecting colorectal cancer recurrence when CEA is rising but CT is negative. PET-CT is not routine for all colorectal cancers — it is added selectively for the specific indications above at MDT recommendation.

Tumour budding is a histological finding where isolated single cancer cells or small clusters of 2–4 cells are seen at the invasive front of the primary tumour — representing an epithelial-to-mesenchymal transition event associated with higher metastatic potential. Tumour budding is an independent adverse prognostic factor in colorectal cancer — particularly in Stage II disease where it identifies high-risk patients who should receive adjuvant chemotherapy. ITBCC (International Tumour Budding Consensus Conference) grading: Bd1 (low budding, 0–4 buds) — low risk; Bd2 (intermediate, 5–9 buds); Bd3 (high budding, 10+ buds) — high risk of nodal metastasis and recurrence. High tumour budding in Stage II colorectal cancer is now included in most guidelines as a high-risk feature justifying adjuvant chemotherapy alongside T4, fewer than 12 lymph nodes, perineural invasion, and lymphovascular invasion.

CEA (Carcinoembryonic Antigen) is the most important post-operative surveillance marker for colorectal cancer. Pre-operative CEA: elevated CEA (above 5 ng/mL) is an independent adverse prognostic factor; CEA above 200 ng/mL strongly suggests hepatic or peritoneal metastases. Post-operative CEA: should normalise (below 5 ng/mL) within 6 weeks of R0 resection — failure to normalise indicates residual disease. Surveillance protocol: CEA every 3 months for 3 years (years 1–3), then every 6 months for 2 years (years 4–5). Rising CEA on surveillance triggers CT chest/abdomen/pelvis — detecting recurrence 3–6 months before clinical symptoms. CEA-triggered detection of liver or lung metastases at an earlier, smaller stage enables potentially curative resection in a higher proportion of patients than symptom-driven investigation. CEA surveillance is the most cost-effective component of colorectal cancer surveillance.

CEA and CA 19-9 are both glycoprotein tumour markers used in GI cancer management — with different specificities. CEA: most valuable for colorectal cancer (elevated in 70–80% of metastatic CRC); also elevated in gastric, pancreatic, lung, and breast cancer; and benign conditions (smoking, liver disease, IBD). CA 19-9: most valuable for pancreatic cancer (elevated in 70–80%) and biliary cancers; also elevated in benign biliary disease, pancreatitis, liver disease, and IBD — reduced sensitivity in Lewis antigen-negative individuals (5–10% of population cannot produce CA 19-9 regardless of cancer). Combined CEA and CA 19-9 improves sensitivity for pancreatic cancer surveillance. Neither marker is sensitive or specific enough for primary cancer diagnosis — they are used for monitoring response to treatment and detecting recurrence in patients with known cancer.

Genetic testing in GI cancer serves three purposes: identify hereditary cancer syndromes (Lynch syndrome, FAP, hereditary diffuse gastric cancer, Peutz-Jeghers syndrome) enabling surveillance and prophylactic surgery for the patient and family; determine tumour molecular characteristics (KRAS, NRAS, BRAF, HER2, dMMR/MSI-H, FGFR2) guiding systemic treatment selection; and identify germline variants that predict drug sensitivity (BRCA1/2 in pancreatic cancer — predicts benefit from PARP inhibitors; POLE mutations in colorectal cancer — predict exceptional response to immunotherapy). Germline (inherited) testing: blood test — identifies hereditary syndromes. Somatic (tumour) testing: from biopsy or surgical specimen — identifies acquired mutations determining treatment. All colorectal cancers: MMR IHC + KRAS/NRAS/BRAF testing standard. All metastatic gastric/GEJ cancers: HER2 IHC + FISH. All pancreatic cancers: germline BRCA testing.

Liquid biopsy analyses circulating tumour DNA (ctDNA) — fragments of cancer cell DNA shed into the bloodstream — from a blood sample. Applications in colorectal cancer: ctDNA detection after curative surgery identifies patients with residual microscopic disease (MRD — Minimal Residual Disease) who are at high risk of recurrence and benefit from adjuvant chemotherapy; monitoring chemotherapy response — falling ctDNA levels confirm response; early detection of recurrence — ctDNA may rise 5–8 months before CT detects imaging recurrence. The DYNAMIC trial demonstrated ctDNA-guided adjuvant chemotherapy decisions in Stage II CRC — ctDNA-negative patients safely avoid chemotherapy, reducing over-treatment without compromising cancer outcomes. Liquid biopsy is not yet standard of care in routine clinical practice — it is increasingly used in clinical trials and at specialist centres as evidence accumulates.

Blue light colonoscopy (BLC) — also called chromoendoscopy or narrow band imaging (NBI) — enhances the detection of flat and sessile colorectal lesions that may be invisible under standard white light. Narrow Band Imaging (NBI): blue and green wavelengths highlight superficial mucosal vasculature — increasing contrast of flat adenomas and sessile serrated lesions. Chromoendoscopy: spraying dilute indigo carmine or methylene blue dye onto the mucosa accentuates subtle surface patterns. Virtual chromoendoscopy: digital image enhancement achieving chromoendoscopy effect without dye application (FICE, i-SCAN). Evidence: blue light colonoscopy techniques increase adenoma detection rate (ADR) by 25–30% over standard white light colonoscopy — particularly for right-sided flat lesions. Blue light techniques are recommended for surveillance colonoscopy in Lynch syndrome and IBD patients where flat dysplasia is the predominant cancer risk.

A very high CEA (above 200 ng/mL) in a patient with colorectal cancer strongly suggests advanced metastatic disease — most commonly hepatic metastases, but also peritoneal spread, lung metastases, or bone disease. The higher the CEA, the greater the estimated tumour volume. A CEA of 200 ng/mL does not automatically mean inoperable — some patients with extensive but resectable liver metastases achieve normalisation of CEA after hepatectomy, followed by long-term survival. CEA above 200 should trigger: CT chest/abdomen/pelvis with contrast; PET-CT if CT is equivocal or shows unexpected findings; consideration of staging laparoscopy before committing to major surgery if peritoneal disease is suspected. The oncological principle remains: a rising CEA drives investigation; the imaging findings determine whether curative surgical intent is appropriate.

MDT review for GI cancer at Sahyadri Manipal Hospital brings together: colorectal or GI surgical oncologist, medical oncologist (who plans chemotherapy), radiation oncologist, specialist GI radiologist (who reports all staging MRI and CT at the meeting), histopathologist (who reviews all biopsy and surgical specimen reports), and specialist nursing team. Every new GI cancer patient is presented and discussed before any treatment begins. MDT outcomes: the correct staging is verified against imaging and pathology; treatment sequence — surgery first versus chemotherapy first — is agreed; the exact surgical approach is planned; and appropriate clinical trial or targeted therapy is considered. Patients who receive MDT-planned treatment have higher rates of guideline-concordant care, lower rates of unnecessary surgery, and improved survival. Dr. Gore presents every new GI cancer patient at MDT at Sahyadri Manipal Hospital before any surgical recommendation.

Diagnostic laparoscopy — a brief keyhole procedure under general anaesthesia — allows direct inspection of the peritoneal cavity, liver surface, and regional lymph nodes before committing to major GI cancer surgery. It identifies pathology below the resolution of CT and PET-CT: peritoneal deposits (carcinomatosis) too small for CT detection; small liver surface metastases; peritoneal adhesions; and omental cake disease. Peritoneal washing cytology is collected — positive cytology upstages to Stage IV without visible deposits. Indications: all locally advanced gastric cancer (T3/T4 on CT — changes management in 15–30%); GEJ cancer before oesophagectomy; selected pancreatic cancers; planning CRS+HIPEC — confirming PCI and CC-0 achievability; and equivocal peritoneal findings on CT before major liver or rectal cancer resection. Diagnostic laparoscopy is a 30–45 minute day procedure with potentially high clinical impact — preventing unnecessary major laparotomy in patients with occult peritoneal disease.

Dietary adjustment after colorectal surgery varies by operation type. After right hemicolectomy: most patients return to normal diet within 4–6 weeks — high-fibre diet is encouraged for bowel health; some patients have looser stools initially. After low anterior resection (before reversal): ileostomy diet applies — low residue, adequate hydration (2–2.5L daily). After reversal: low-residue diet for 4–6 weeks then gradual return to normal; 4–8 loose stools daily initially is expected (LARS) — avoid high-fibre, spicy, and greasy foods in the first 3 months; eat smaller more frequent meals; time meals predictably. After total gastrectomy: 6–8 small meals daily; avoid refined sugar (dumping syndrome); no drinking during meals; B12 injections monthly for life; dietitian review every 3–6 months. After Whipple surgery: pancreatic enzyme supplementation (Creon) with every meal — the pancreatic head and its enzyme secretion are removed; dietary fat restriction initially.

Exercise is strongly encouraged after GI cancer surgery — but introduced gradually. Week 1–2: walking only — start with 5–10 minutes daily, increasing to 30 minutes by week 2; no lifting. Week 3–4: increase walking duration and pace; light household activities. Week 4–8: progressive return to normal activity; no lifting above 5kg for 8 weeks after major abdominal surgery (risk of hernia at port sites and extraction wound). Week 8–12: gym and strengthening exercises if clinically cleared; swimming after week 6 if wound is fully healed. Running and sport: typically from 12 weeks with stoma reversal completed or stoma well-established. Long term: regular exercise (150 minutes moderate aerobic per week) reduces colorectal cancer recurrence risk by 30–40% in multiple prospective studies — the most evidence-based lifestyle intervention for CRC survivors. Pelvic floor exercises are started immediately after rectal cancer surgery.

Post-operative surveillance for colorectal cancer aims to detect recurrence at an early, potentially curable stage. Standard protocol (NCCN and ESMO guidelines): CEA every 3 months for 3 years, then every 6 months for 2 years; CT chest/abdomen/pelvis every 6 months for 3 years, then annually for 5 years; colonoscopy at 1 year post-surgery (or 3–6 months if pre-operative colonoscopy was incomplete due to obstructing tumour); repeat colonoscopy at 3 years then every 5 years. High-risk patients (Lynch syndrome, FAP): annual colonoscopy for life. Most recurrences occur within the first 3 years — the schedule is front-loaded for this reason. A rising CEA on surveillance triggers urgent CT — early detection of liver or lung metastases enables potentially curative resection in 30–50% of patients with limited disease.

GI cancer surgery — particularly operations involving stoma, LARS, sexual dysfunction, or body image changes — has a significant psychological impact on many patients. Recognised challenges: depression (affecting 25–30% of GI cancer patients in the first year — a medical condition requiring treatment, not a weakness); anxiety about cancer recurrence (particularly around surveillance scans — 'scanxiety'); body image changes with stoma or weight loss; sexual function changes (erectile dysfunction after rectal cancer; dyspareunia in women after pelvic surgery); and fatigue lasting 3–6 months after major surgery. Resources: Dr. Gore's team provides referral to clinical psychology and psychosexual counselling for patients experiencing these difficulties; peer support — speaking to someone who has navigated similar surgery — is invaluable; the Indian Ostomy Association and cancer support groups provide community. If dark thoughts or persistent low mood occur at any time: contact Dr. Gore's team immediately.

Cancer-related fatigue (CRF) is the most common and distressing symptom experienced by GI cancer patients — affecting 70–80% during treatment and 30–40% long-term. CRF differs from normal tiredness — it is not relieved by rest and is disproportionate to activity. Causes: surgery (physiological stress of major operation); chemotherapy (bone marrow suppression, systemic inflammation); radiotherapy; anaemia; hypothyroidism; sleep disturbance; depression; and the cancer itself. Management: the single most effective evidence-based treatment for CRF is graded aerobic exercise — walking, swimming, or cycling 3–5 times weekly; structured sleep hygiene; energy conservation strategies; treatment of reversible causes (anaemia — iron, EPO; hypothyroidism — thyroxine; depression — antidepressants or CBT). CRF typically improves over 6–12 months after completing treatment. Patients should not minimise fatigue — it must be communicated to the oncology team to identify and treat reversible causes.

Return to work timeline depends on the operation and the type of work. Desk or sedentary work: 2–4 weeks after laparoscopic colectomy; 3–4 weeks after robotic LAR (with ileostomy); 4–6 weeks after stoma reversal. Physical or manual work: 6–8 weeks after colectomy; 8–12 weeks after LAR/APR with pelvic reconstruction. Work involving heavy lifting (above 15kg): 12 weeks minimum after major abdominal surgery to allow adequate abdominal wall healing and reduce incisional hernia risk. LARS: frequent bowel movements and urgency may affect ability to work far from toilet facilities in the first 3–6 months after stoma reversal — open discussion with the employer about flexible working arrangements or proximity to facilities is recommended. Many patients find a phased return to work — starting part-time and progressively increasing hours — improves recovery. A medical fitness-to-work certificate is provided at the post-operative consultation.

Colorectal cancer recurrence risk depends on stage: Stage I — under 5%; Stage II — 15–25% (higher with high-risk features); Stage III — 30–50%. Recurrence is most common in the first 3 years. Evidence-based strategies to reduce recurrence: adjuvant chemotherapy (FOLFOX or CAPOX for Stage III reduces recurrence by 30%); regular structured exercise (150 min/week reduces recurrence risk by 30–40%); maintaining healthy body weight (obesity increases recurrence risk); not smoking (smoking increases recurrence risk and all-cause mortality); aspirin (regular aspirin reduces colorectal cancer recurrence risk — particularly for high-risk patients; discuss with oncologist before starting); and strict surveillance adherence — detecting and treating early recurrence at an operable stage. The most important recurrence-reducing strategy at the surgical level is achieving R0 resection with quality TME at a specialist centre in the first place.

Sexual dysfunction after rectal cancer surgery is common — caused by injury to the autonomic nerve plexuses in the pelvis during TME. In men: erectile dysfunction (inability to achieve or maintain erection) occurs in 10–40% depending on surgical approach, patient age, and pre-operative baseline; retrograde ejaculation may occur from hypogastric nerve injury. In women: dyspareunia (painful intercourse), vaginal dryness, and reduced sensation from pelvic nerve injury; anterior dissection affecting vaginal wall. Prevention: robotic TME with careful nerve-sparing dissection reduces rates significantly versus open surgery — the REAL trial confirmed robotic superiority in autonomic nerve preservation. Management: erectile dysfunction — phosphodiesterase-5 inhibitors (sildenafil, tadalafil) are effective and should be tried early; vacuum erection devices and penile injection therapy. Women: local oestrogen, pelvic floor physiotherapy, and lubricants. Psychosexual counselling — highly effective and recommended for all affected patients. Discuss with Dr. Gore's team at 3-month post-operative review.

Post-Whipple nutritional management is complex and requires long-term specialist attention. Pancreatic exocrine insufficiency (PEI) — loss of pancreatic enzyme secretion — causes fat malabsorption (steatorrhoea — fatty, malodorous stools), weight loss, and fat-soluble vitamin deficiency (A, D, E, K). Treatment: pancreatic enzyme replacement therapy (PERT) — Creon (pancreatin) capsules taken with every meal and snack, titrating the dose until stools normalise. Pancreatic endocrine insufficiency — new-onset diabetes mellitus or worsening of pre-existing diabetes from loss of insulin-producing islet cells — managed with diet, oral hypoglycaemics, or insulin with endocrinology input. Nutritional monitoring: weight, albumin, pre-albumin, fat-soluble vitamins, HbA1c, and blood glucose — at every oncology review. Jejunostomy tube placed at surgery for early post-operative feeding when oral intake is delayed. Dietitian review every 3 months for the first year after Whipple surgery.

Palliative care for advanced GI cancer is not 'giving up' — it is specialised care focused on quality of life, symptom management, and supporting patients and families through serious illness. Components: symptom management — pain (WHO analgesic ladder, nerve blocks for refractory pain), nausea, bowel obstruction, ascites, jaundice (stenting), fatigue, and dysphagia; psychological and emotional support — addressing anxiety, depression, existential distress, and relationship impacts; nutritional support — when oral intake is inadequate, parenteral or enteral nutrition may be appropriate; spiritual and cultural care; and advance care planning — helping patients articulate their wishes for end-of-life care. Palliative care is most effective when integrated early with cancer treatment — not reserved for the final weeks of life. Early palliative care integration (ASCO recommends from diagnosis of Stage IV cancer) improves quality of life, reduces aggressive end-of-life treatment, and paradoxically may improve overall survival (Temel, NEJM 2010).

Dr. Vinod T. Gore is one of India's most senior GI and colorectal surgical oncologists — 30+ years dedicated exclusively to cancer surgery. Training: 5-year Surgical Oncology residency at Tata Memorial Hospital, Mumbai (one of Asia's leading cancer centres); 3 years plastic and reconstructive surgery at Sassoon General Hospital, Pune. Qualifications: MS General Surgery (ranked 2nd); FAIS; FIAGES; FARIS — Fellow in Advanced Robotic and Innovative Surgery, University of Edinburgh. GI cancer expertise: colorectal cancer (robotic TME, LAR, APR, ISR, sphincter preservation, stoma care); gastric cancer (D2 gastrectomy, FLOT protocol); oesophageal cancer (RAMIE, CROSS protocol); HPB cancer (Whipple, hepatectomy, CRLM, HIPEC for peritoneal disease); and appendiceal PMP. Department Head Surgical Oncology, Sahyadri Manipal Hospital Pune since 2009. MMC Registration: 90942.

cancerclinicpune.com is the dedicated Colorectal and GI Cancer Centre website of Dr. Vinod T. Gore — providing comprehensive patient education, condition information, and surgical programme details for: colorectal cancer (colon, rectal, anal); upper GI cancer (stomach, oesophageal, GEJ); hepatopancreaticobiliary (HPB) cancer (liver, pancreatic, bile duct, gallbladder); GIST and neuroendocrine tumours; HIPEC for peritoneal disease; and robotic GI surgery. The Knowledge Hub provides FAQ, Shorts, Video, Slideshow, and Blog educational content. Related specialist sites: cancersurgeons.in (comprehensive cancer surgery); bestroboticsurgeonpune.in (robotic surgery programme); silverleafclinic.com (clinic website). Consultations at Silver Leaf Clinic, Hadapsar, Pune. Call 88558 10010.

Silver Leaf Clinic: 511, City Centre, Solapur Road, Opposite Vaibhav Theatre, Hadapsar, Pune 411028. Google Maps: search 'Dr Vinod Gore Silver Leaf Clinic Hadapsar'. Accessible from: Hadapsar, Fatima Nagar, Kharadi, Magarpatta City, and the Pune-Solapur highway. OPD hours: Monday to Saturday, 10:00 AM to 6:00 PM. Sunday: by prior appointment only. All GI cancer surgery consultations, second opinions, and post-operative follow-up at Silver Leaf Clinic. Major operations at Sahyadri Manipal Hospital, Hadapsar. Call 88558 10010 to book your GI cancer surgery consultation. WhatsApp 84118 08284 for outstation patients or report sharing.

Silver Leaf Clinic OPD: 88558 10010 — for appointment booking and general consultation queries. Silver Leaf Clinic Landline: +91 20 6768 9704. Dr. Gore Direct and WhatsApp: 84118 08284 — for outstation patients, sharing CT/MRI/PET-CT images and biopsy reports via WhatsApp before the consultation, video consultation scheduling, and urgent clinical queries. Outstation patients can send imaging and pathology reports via WhatsApp for preliminary review before travelling to Pune. Video teleconsultation is available for second opinion and pre-operative planning. Address: 511 City Centre, Solapur Road, Hadapsar, Pune 411028. OPD: Monday–Saturday, 10AM–6PM.

To book a consultation with Dr. Gore for colorectal or GI cancer surgery at Silver Leaf Clinic, Hadapsar: call 88558 10010 (OPD) or WhatsApp 84118 08284 (direct). OPD hours: Monday–Saturday, 10AM–6PM. What to bring: CT/MRI/PET-CT scans on CD or shared via WhatsApp; all biopsy and histopathology reports with IHC; colonoscopy or endoscopy reports; blood investigations (CBC, LFT, KFT, CEA, CA 19-9 where relevant); previous operative notes if surgery has occurred; and any chemotherapy or radiotherapy treatment summaries. Outstation patients: arrange preliminary video consultation via WhatsApp 84118 08284 before travelling. Urgent oncological cases — new diagnosis, acute obstruction, rising CEA — are prioritised for same-day or next-day appointments where clinically necessary.

A second surgical opinion is strongly encouraged for: any patient told their colorectal cancer is inoperable; any patient told they need a permanent stoma (APR) for rectal cancer; any patient with colorectal liver metastases labelled inoperable; complex GI cancers (HIPEC candidates, Whipple candidates); and any patient wanting independent confirmation of their treatment plan. A second opinion involves reviewing all your imaging (CT, MRI, PET-CT — on CD or WhatsApp), biopsy reports, and treatment records independently. Many patients told inoperable at general hospitals are successfully operated at Dr. Gore's specialist centre after expert review. To arrange a second opinion: call 88558 10010 or WhatsApp 84118 08284. A written clinical opinion can be provided for reference with your original treating team if requested.

Dr. Vinod T. Gore — 30+ years surgical oncology, Tata Memorial Hospital trained, FARIS Edinburgh, ET Trailblazer Leaders in Oncology 2025, Department Head Surgical Oncology Sahyadri Manipal Hospital. His colorectal cancer programme at Sahyadri Manipal Hospital Pune covers: robotic TME for rectal cancer; robotic colectomy with CME; sphincter preservation and ISR for low rectal cancer; HIPEC for peritoneal metastases; and robotic hepatectomy for liver metastases. OPD at Silver Leaf Clinic, 511 City Centre, Solapur Road, Hadapsar, Pune 411028. Call 88558 10010 to book. Full programme at cancerclinicpune.com. For robotic surgery details: bestroboticsurgeonpune.in. For general cancer surgery: cancersurgeons.in.

Sahyadri Manipal Hospital, Hadapsar, Pune — the designated Robotic Cancer Surgery Centre of Excellence (ARIS accredited) — is the primary operating hospital for Dr. Gore's GI cancer surgery programme. The hospital provides: da Vinci Xi robotic platform for all major GI cancer operations; dedicated HPB and colorectal surgery team; ICU with experienced anaesthesiology team managing major GI cancer operations; multidisciplinary tumour board weekly GI cancer MDT; specialist stoma and wound care nursing; and oncology wards with experienced surgical nursing. The combination of a dedicated surgical oncologist (Dr. Gore), an ARIS-accredited robotic programme, a full MDT, and experienced support teams makes Sahyadri Manipal Hospital, Hadapsar the specialist centre of choice for GI cancer surgery in Pune.

Dr. Gore's recognition for GI and oncological surgery: Trailblazer Leaders in Oncology — Economic Times Onco Frontiers Meet 2025 — his primary award, recognising pioneering contributions to surgical oncology in India with GI cancer surgery a major component; Best Robotic Oncosurgeon — Navbharat Times 2024 — acknowledging leadership in robotic GI cancer surgery in Pune; Asia Pioneer of Electrochemotherapy — introducing ECT in Asia in 2013 for GI and other cancer deposits; Dr. Jejurkar Award; and academic recognition including Organising Secretary roles at MOGCON 2018, ICON 2023, and Best of ASCO 2024. These recognitions reflect 30+ years of sustained excellence and innovation in cancer surgery — not a single achievement but a career of contribution to oncosurgical standards in India.

Yes. Video teleconsultation is available for outstation patients across India and international patients who cannot travel to Pune immediately. Process: WhatsApp 84118 08284 with your name, contact details, a brief description of the cancer diagnosis and stage, and all available imaging (CT, MRI, PET-CT as image files or PDF) and biopsy reports. The team confirms a consultation time. Video consultations address: case review and resectability assessment; second opinion on inoperability; pre-operative planning and neoadjuvant chemotherapy advice; and post-operative follow-up review for established patients. Outstation patients from Maharashtra, Gujarat, Goa, Madhya Pradesh, and internationally travel to Pune for surgery after initial video consultation. Reports can be reviewed on WhatsApp immediately for urgent cases. For in-person consultation at Silver Leaf Clinic, Hadapsar, Pune: call 88558 10010.

The Knowledge Hub at cancerclinicpune.com provides five formats of GI cancer patient education. FAQ: 200 expert questions and answers on colorectal and GI cancer surgery — the section you are reading now. Shorts: brief 2–3 minute explainer videos on key GI cancer topics — stoma care, LARS, what is HIPEC, and more. Video: longer patient education and surgical animation videos covering major GI operations. Slide Show: visual guides to conditions and procedures — colon cancer staging, rectal cancer surgery, stoma care guide. Blog: in-depth patient articles — 'Life After a Stoma', 'Understanding LARS', 'When Are Liver Metastases from Colon Cancer Operable', and more. All Knowledge Hub content is written and reviewed by Dr. Gore to ensure clinical accuracy and patient accessibility. New content is added regularly. Visit cancerclinicpune.com for the full Knowledge Hub.

Yes. Sahyadri Manipal Hospital, Hadapsar accepts cashless insurance from most major TPA networks including Star Health, HDFC ERGO, New India Assurance, United India, National Insurance, and Bajaj Allianz. Pre-authorisation from the TPA must be obtained before planned admission. Ayushman Bharat (PMJAY) government scheme coverage is available for eligible patients — bring your Ayushman card to the consultation. MJPJAY (Maharashtra government scheme) is also accepted. The hospital billing department provides a detailed cost estimate before surgery — including surgical fees, anaesthesia, robotic consumables, ICU, ward, and medications. GI cancer surgery costs vary significantly by procedure (colonoscopy, colectomy, Whipple, hepatectomy, HIPEC) — contact Sahyadri Manipal Hospital billing department after the OPD consultation at Silver Leaf Clinic for an accurate, itemised estimate.

For a productive first GI cancer surgery consultation with Dr. Gore, bring: CT chest/abdomen/pelvis on CD or USB (or share via WhatsApp 84118 08284 before the appointment); pelvic MRI on CD for rectal cancer; PET-CT if performed; colonoscopy or endoscopy report with biopsy findings; histopathology report with full IHC panel (MMR status, HER2, KRAS/NRAS/BRAF where tested); blood investigations — CBC, LFT, KFT, CEA, CA 19-9; previous operative notes and surgical pathology if prior cancer surgery has occurred; chemotherapy or radiotherapy treatment summaries including drug names, cycles, and response assessment CT; and a complete list of current medications. The more complete the information provided, the more specific and clinically actionable the consultation will be for both you and Dr. Gore.

The timeline from first consultation to surgery depends on the urgency, pre-operative investigations needed, and whether neoadjuvant treatment is required. Urgent cases (obstruction, perforation, acute bleeding): surgery within 24–72 hours of presentation. Elective cases — surgery first: pre-operative investigations (CT, MRI, colonoscopy, blood tests, cardiac assessment) take 1–2 weeks; MDT review; surgical date booking — typically surgery within 2–4 weeks of consultation. Elective cases — neoadjuvant treatment first (rectal cancer chemoradiation, gastric FLOT): 5–6 weeks of chemoradiation, or 8 cycles of FLOT (4 months); restaging imaging; surgery 4–8 weeks after completing neoadjuvant treatment. HIPEC cases: staging laparoscopy first (1–2 weeks); HIPEC at a planned date — total time from consultation to surgery typically 3–6 weeks. Dr. Gore's team coordinates investigation scheduling and surgical dates efficiently to minimise waiting time.

cancerclinicpune.com represents a comprehensive, specialist-led GI cancer surgery programme that combines four distinctive strengths. Subspecialty depth: 30+ years of GI and colorectal surgical oncology expertise — Tata Memorial Hospital trained — covering every GI cancer from routine polypectomy to the most complex pelvic exenteration and HIPEC. Robotic leadership: FARIS Edinburgh certified, ARIS Centre of Excellence at Sahyadri Manipal Hospital — robotic TME, ISR, gastrectomy D2, Whipple, RAMIE, and hepatectomy all available. Peritoneal cancer programme: CRS+HIPEC for colorectal, appendiceal, ovarian, and mesothelioma peritoneal disease — one of very few specialist HIPEC centres in western India. Patient-centred care: comprehensive Knowledge Hub education, dedicated stoma nursing, LARS rehabilitation, MDT-based decision-making, and transparent second opinion consultations. Call 88558 10010 to book.